Diastereoselective synthesis of [alpha]-tocopherol by Buss, Axel Wolfgang
    
 
Diastereoselective Synthesis of 
 
α-Tocopherol 
 
 
INAUGURALDISSERTATION 
 
zur 
Erlangung der Würde eines Doktors der Philosophie 
 
 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel  
 
 
von 
 
Axel Wolfgang Buss 
 
aus 
 
Deutschland 
 
 
Basel, 2008 
 
    
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von: 
 
 
 
Prof. Dr. Wolf-Dietrich Woggon 
 
 
 
Prof. Dr. Marcel Mayor 
 
 
Basel, den 11. November 2008 
 
 
Prof. Dr. Eberhard Parlow (Dekan) 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
Table of Contents 
 
Chapter 1:   Introduction       1 
 
 1.1 Vitamin E        1 
 1.1.1 History and Discovery of Vitamin E               1 
 1.1.2 Structure and Occurrence of Vitamin E    2 
1.1.3 Biological Activity of Vitamin E     4 
1.1.4 The Biosynthesis of Vitamin E     7  
1.1.5 The Tocopherol Cyclase      10 
1.1.6 A Biomimetic Chromanol Cyclisation     12 
1.1.7 Industrial Synthesis of “Vitamin E”         15 
1.1.8 First Total Synthesis of SRR- and RRR-α-Tocopherol   17
 1.1.9 A Short Route to α-Tocopherol      20  
 
1.2 Supramolecular Chemistry and Enzyme Mimetics  23 
1.2.1 What is supramolecular chemistry?     23 
1.2.2 Cyclodextrins         24  
1.2.2.1 Molecular Structure and Chemical Properties     24 
1.2.2.2 Cyclodextrin Based Enzyme Mimics     27 
1.2.3 β-CD based enzyme mimic of β,β-carotene-15,15’-moooxygenase: the 
essential contributions from “Woggon group”               33 
 
Chapter 2:   Aims of this Work      37 
 
Chapter 3:    Results and Discussion      39 
 
3.1 Cyclodextrin Modified on Primary Face      39 
3.1.1 Attachment of a Tris(2-pyridylmethyl)amine (TPA) Derived Ligand to β-
Cyclodextrin          39 
3.1.2 Application of the β-CD Linked Pentadentate Nitrogen Ligand 91 in 
Catalytic Oxidation Reactions       42 
3.1.3 Design of a Novel CD-linked Salen Ligand    45 
3.1.4 Catalytic Experiment with CD-catalyst     48 
    
3.1.5 A CD-Modified Ketone Catalyst      49 
 
3.2 Organocatalytic Asymmetric Epoxidation of Protected Phytyl 
        Hydroquinones 84 by Chiral Ketones      52 
3.2.1 Introduction          52 
3.2.2 Synthetic Strategy for the Synthesis of α-Tocopherol via Shi 
          Epoxidation According to Figure 27      58 
3.2.3 Asymmetric Shi epoxidation of protected phytyl hydroquinone 
          derivatives 84               59 
3.2.4 Transformation of Chiral Epoxide 147 to α-Tocopherol (1) via Acid 
Supported Epoxide Ring Opening       66 
3.2.5 An Alternative Synthetic Pathway for the Transformation of Alkene 132 
to α-Tocopherol (1) using Catalyst 114                69 
 
Chapter 4:    Summary and Conclusions      73 
 
Chapter 5:     Experimental Part      76 
 
5.1 General Remarks        76 
5.1.1 Solvents and Reagents      76 
5.1.2 Materials and Instruments      76 
 
5.2 Syntheses        79 
5.2.1 Syntheses of Cyclodextrin Catalysts and Catalytic  
Reactions                                                              79 
 5.2.2 Synthesis of L-fructose-derived Shi-ketone catalyst ent-114 
Mesylate 138        89 
5.2.3 Synthesis of bis-protected phytyl hydroquinones  92 
5.2.4 Epoxidation of bis-protected phytyl hydroquinone substrates 105 
5.2.5 Cyclisation of 149 to furan 150                                        111 
5.2.6  Synthesis of α-Tocopherol (1) via Epoxide 148   112 
 
 
 
    
Chapter 6:  Appendix       115 
 
 6.1 List of Abbreviations                                                        115 
 6.2 References                                                                        118  
 6.3 Curriculum Vitae                                                        123 
 6.4 Publications and Presentations                                   124 
 6.5 Eidesstattliche Erklärung                                                 125                        
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Introduction 
 - 1 -   
1 Introduction 
 
1.1 Vitamin E 
 
1.1.1 History and Discovery of Vitamin E 
 
Vitamin E is the collective name given to a family of biologically active molecules 
called tocopherols and tocotrienols. In 1922, the discovery of vitamin E by Evans and 
Bishop resulted from a rat feeding study in which a diet of purified foods (casein 18%, 
cornstarch 54%, lard 15%, butterfat 9%) with essential salts (4%) and known vitamins 
(vitamin A (as cod liver oil), vitamin B (as yeast) and vitamin C (as orange juice)) was 
shown to produce adverse effects to pregnant females leading to fetus resorption.1 
However, when fed with fresh lettuce such symptoms were no longer observed and 
therefore upon the addition of certain vegetable products the reproductive ability of 
the rats could be restored. Consequently, an unknown nutrient was shown to be 
essential for fetal development. They concluded: “natural foods, as opposed to 
purified diets contained a substance not needed for normal growth, but essential for 
reproduction.” In 1924, Sure observed independently of Evans that a missing nutrient 
in the diet was responsible for making rats sterile and he termed this missing nutrient, 
Vitamin E because vitamins A, B, C and D were at this time already known.2  Intense 
investigations were undertaken by Evans et al., however, little progress was 
observed until 1936 when a fat soluble molecule possessing the properties ascribed 
to the unknown molecule Vitamin E was extracted from wheat germ oil.3  They called 
the substance tocopherol. The name is derived from the ancient Greek word phero, 
“to bring” and the word tocos, meaning “childbirth”. The structure of this molecule was 
elucidated in 1936 and today this molecule is called α-tocopherol (1) (figure 1). In the 
following years the three remaining tocopherols, β-, γ-, and δ-tocopherol (2 - 4) were 
isolated.4, 5 In 1963 the (R)-configuration could be assigned to the three stereo 
centers of α-tocopherol for the first time, by Isler and coworkers.6 About at that time 
the four remaining members of the vitamin E family, the tocotrienols 5 - 8, were 
isolated,7 which also showed vitamin E activity. Consequently, there are in total four 
tocopherols and four tocotrienols known today, which belong to the vitamin E family 
and occur in nature. 
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Figure 1:  Natural vitamin E analogues 
 
 
1.1.2 Structure and Occurrence of Vitamin E 
 
Natural vitamin E comprises eight different forms which are all derived from 
6-chromanol, the α-, β-, γ-, and δ-tocopherols and the α-, β-, γ-, and δ-tocotrienols. 
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The tocotrienols have an unsaturated isoprenoid side chain with three trans double 
bonds at the 3', 7' and 11' positions and possess one stereo centre with R 
configuration at C(2).  In contrast the tocopherols also contain a trimethyltridecyl tail 
and possess three chiral centres at the 2, 4’, 8’ positions which naturally occur in the 
R,R,R configuration (figure 1). These compounds are only synthesised by plants and 
other oxygenic, photosynthetic organisms, but they are essential components of the 
diet of animals. Plants produce a range of tocochromanols which vary in their 
abundance and compositions and in general, photosynthetic plant tissues contain 
from 10 to 50 μg of tocochromanols per g fresh weight. Despite these variations, 
α-tocopherol is often the principle tocochromanol in leaves.  
 
Seed oils are a major source of vitamin E for the human diet and the compositions of 
tocopherols in some unrefined oils are listed in table 1. Sunflower and olive oils are 
good sources of α-tocopherol and palm oil of the tocotrienols. In general, tocotrienols 
tend to be more abundant in seeds of monocots, such as wheat, rice and barley.8  
 
 1 2 3 4 5 6 7 8 
palm 89 - 18 - 128 - 323 72 
soybean 100 8 1021 421 - - - - 
maize 282 54 1034 54 49 8 161 6 
sunflower 670 27 11 1 - - - - 
rapeseed 202 65 490 9 - - - - 
 
Table 1: Tocopherol and tocotrienol contents (mg/Kg) in some seed oils.9 
 
 
In human plasma of unsupplemented individuals, α-tocopherol is found on average at 
concentrations of 22–28 μM, which is 10 and 100 times higher than the 
concentrations of γ-tocopherol (2.5 μM) and of δ-tocopherol (0.3 μM), respectively.10, 
11 The highest content of α-tocopherol is found in adipose tissue (150 μg/g tissue) 
and the adrenal glands (132 μg/g tissue). Other organs such as the kidneys, heart or 
liver contain between 7 and 40 μg/g tissues. In contrast erythrocytes have a relatively 
low content of 2 μg/g tissue.12, 13 Of the eight vitamin E family members only α-
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tocopherol (and to a much lesser extent γ-tocopherol) appears to be retained in 
significant amounts by a living organism.14 
 Relatively recently, novel natural vitamin E analogues have been discovered. For 
example, palm oil also contains small amounts of α-tocomonoenol, and some marine 
organisms also contain marine derived tocopherol (MDT), with a single unsaturated 
bond at the end of the side chain, which is assumed to be the result of cold-water 
adaptation.15, 16 α-Tocopheryl phosphate has recently been detected at low levels in 
liver and adipose tissue, and it is possible that it may be an ubiquitous constituent of 
animal and plant tissues (figure 1).17, 18  
 
 
1.1.3 Biological Activity of Vitamin E 
 
As already mentioned Vitamin E was discovered in 1922 by Evans and Bishop as a 
necessary dietary factor for reproduction in rats.1 Many other disorders and diseases 
are thought to be in connection with a Vitamin E deficiency.19, 20 Among them are:  
 
• Many types of cancer   
• Atherosclerosis and other circulatory diseases 
• Arthritis 
• Cataract formation 
• Senile dementia (Alzheimer type) 
• Respiratory diseases induced by pollution 
 
Some foods become rancid when they are stored, which is a sign that the lipid 
material, i.e., the fats, in the food have undergone a chemical reaction with 
atmospheric oxygen. Such oxidations that occur under mild conditions are called 
autoxidations21, or, in biological circles, lipid peroxidations (figure 2).  
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Figure 2: Autoxidation of lipids (RH). 
 
The first step for each chain involves the production of a lipid-radical (R •). Such chain 
initiation may occur by the reaction of a lipid (RH) with a reactive oxygen-species. In 
general, the oxidation of lipids is known to proceed by a chain process mediated by a 
free radical, in which the lipid peroxyl radical (ROO •) serves as a chain carrier. These 
peroxyl radicals are trapped in the presence of tocopherols (ArOH) because the 
tocopheroxyl radicals (ArO•) formed are more stable (figure 2) due to resonance 
stabilization. Consequently they do not continue the chain, but are eventually 
destroyed by reaction with a second peroxyl radical or with two electron oxidants 
(such as peroxynitrite, ONOO-). This yields 8α-substituted tocopherones, which are 
readily hydrolysed to 8α-hydroxy tocopherones. These then rearrange spontaneously 
to form α-tocopheryl quinones (figure 3).22 In an alternative pathway, epoxy-α-
tocopheryl quinones are also formed.23 
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HO
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tocopheryl hydroquinone  
Figure 3: Oxidation products of α-tocopherol. 
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In comparison to simple phenols, α-tocopherol (1) is the more effective antioxidant. It 
could be shown that stabilization of the phenoxyl radical in α-tocopherol is maximized 
due to the optimized interaction of the orbital of the ring-oxygen with the half-
occupied molecular orbital (SOMO) of the phenoxyl radical (figure 4).24 Additionally, 
the completely substituted phenol-ring with three methyl-groups also has a stabilizing 
effect on the radical. 
 
O
O
R
O O
R  
  
Figure 4: Resonance stabilization of the tocopheroxyl radical. 
 
In plant and animal tissues, tocopherols can be regenerated from the tocopheroxyl 
radicals in a redox cycle mediated by a number of antioxidants, including vitamins A 
and C and coenzyme Q, this greatly extends their biological potency.25 Vitamin C 
(ascorbate) may be especially important in aqueous systems, although it may also 
act at the surface of membranes.26  
 
The materials that are most readily autoxidised in living organisms and hence in most 
need of protection are the polyunsaturated fatty acids. Like other fatty acids, these 
form part of various lipid materials within the organism including, particularly, 
biomembranes. The protection of organic material, including living organisms, 
against oxidative degradation is provided by fairly small quantities of certain specific 
compounds called antioxidants.27 Such compounds can be divided into two broad 
classes, referred to as preventive antioxidants, which reduce the rate of chain 
initiation, and chain-breaking antioxidants (ArOH in figure 2). 
 
It has been proposed by Traber and Atkinson that all of the observations concerning 
the in vivo mechanism of action of α-tocopherol result from its role as a lipid-soluble 
chain-breaking antioxidant, a so-called peroxyl radical scavenger. The importance of 
this function is to maintain the integrity of long-chain polyunsaturated fatty acids and 
thus maintain their bioactivity. These bioactive lipids are important signalling 
molecules. Changes in their amounts, loss due to oxidation, or their oxidation 
products are the key cellular events that are responded to by cells.28 This hypothesis 
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is supported by studies in plants where the genes for vitamin E synthesis are 
missing.29 
 
In animals, all tocopherols are absorbed to a similar extent in the intestines and are 
transported to the liver mainly in chylomicrons. Despite the fact that all members of 
the vitamin E family have similar antioxidant functions in vitro (rate constants for H-
atom donation are within an order of magnitude), α-tocopherol is preferentially 
utilized and re-exported by the hepatic α-tocopherol transfer protein (α-TTP).30 
Moreover defects in the human α-TTP31 lead to severe vitamin E deficiency.32 
 
α-TTP is responsible for maintaining plasma α-tocopherol concentrations.33 The 
important structural features of the ligand for recognition by α-TTP include:  
(1) A fully methylated chroman ring.  
(2) A phytyl pyrophosphate-derived tail34 (trimethyltridecyl-residue).  
(3) The R-configuration at C(2) where the tail attaches to the chromanol ring.35 
This third requirement makes α-TTP selective for the 2R-isomers of synthetic all-rac-
α-tocopherol. Thus only natural α-tocopherol (RRR-α-tocopherol) and 
2R-α-tocopherols in synthetic α-tocopherol, are maintained in human plasma and 
tissues by α-TTP unlike the remaining forms of vitamin E.36 
 
 
1.1.4 The Biosynthesis of Vitamin E 
 
Enzymes required for the biosynthesis of vitamin E are found specifically in 
chloroplasts37, 38, 39 and chromoplasts.40 Two substrates are required for vitamin E 
biosynthesis: Homogentisate (11) and a C20 prenyldiphosphate (either 
geranylgeranyldiphosphate for tocotrienols or phytyldiphosphate (12) for 
tocopherols).  Homogentisate (11) supplies the aromatic ring of the chromanol head 
group and is derived from tyrosine (9), which itself is biosynthesised via the shikimate 
pathway. Tyrosine is deaminated to p-hydroxy-phenylpyruvate (10), which in turn is 
oxygenated to homogentisate (11).  The prenyl groups, which are also required, are 
supplied by the 1-deoxy-D-xylulose-5-phosphate pathway.41  
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The first step of vitamin E biosynthesis is the transfer of a prenyl group to 
homogentisate (11). This transfer involves a condensation and a decarboxylation42 
and occurs via either homogentisate phytyltransferase or homogentisate 
geranylgeranyl-transferase. The substrate specificity of the prenyltransferase 
determines whether the final tocochromanol will be a tocopherol or a tocotrienol. In 
order to have γ- or  α-tocochromanols, the number 3 position on the benzoquinol ring 
must be methylated. This methylation step is omitted when β- and δ-tocochromanols 
are produced. The enzyme that catalyses this reaction is called 2-methyl-6-
prenylbenzoquinol methyltransferase. Recent work shows that this enzyme shows no 
activity towards β- and δ-tocopherols.43, 44 Consequently, if the 3 position is 
methylated, it appears that this methylation must happen prior to the cyclization step.   
 
Ring closure to the chromanol head group is performed by tocopherol/tocotrienol 
cyclase45 from a benzoquinol intermediate. The product is either γ- or δ-
tocochromanol. The activity shows little, if any, preference for phytylated substrates 
over geranylgeranylated substrates.46, 47 Thus, tocopherol/tocotrienol cyclase 
produces both γ- and  δ-tocopherols as well as γ- and  δ-tocotrienols. 
 
The final step of the synthesis of α- or β-tocochromanols is the methylation of carbon 
5 on the chromanol ring. This is catalyzed by tocopherol/tocotrienol methyl-
transferase (figure 5).48  
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Figure 5: Biosynthesis of γ- (3) and α-tocopherol (1). 
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1.1.5 The Tocopherol Cyclase 
 
The tocopherol cyclase was isolated in the Woggon group from cultures of the blue-
green algae Anabaena variabilis KUETZING (Cyanobacteria).49 The rationale for this 
enzyme isolation was the hope to find a replacement for the difficult synthetic 
cyclisation step in the preparation of R,R,R-tocopherols by an enzymatic process. It 
could be shown that the isolated tocopherol cyclase was able to cyclize 2,3-dimethyl-
5-phytylhydroquinone (14) to γ-tocopherol (3) (figure 5) with nearly quantitative 
substrate turnover under precisely defined conditions.49 
 
In order to fully understand the mechanism of the enzymatic cyclisation, three 
independent possible routes were considered (figure 6):50  
 
Route A involves the stereospecific hydration of the (E)-double bond of (O4-18O)-14 
followed by cyclisation to give (3S)-(3-2H)-3 via the intermediate (O4-18O, 2'-2H)-15. 
This cyclisation would proceed under retention of configuration at the tertiary alcohol 
in (O4-18O, 2'-2H)-15. This last step had already been exploited in the stereospecific 
acid catalyzed, non-enzymatic ring-closure in the total synthesis of α-tocopherols 
(figure 6).51  
 
The second possible pathway is illustrated as Route B in Figure 6. This 
pathway involves the reverse addition of H2O (or any other species like HS-
enzyme) to the double bond of (O4-18O)-14 which would yield 16 as an alcohol (or 
thio adduct).  This could in turn cyclise under inversion of configuration by attack of 
the phenolic O-atom to give (3R)-(1-18O,3-2H)-3. 
 
The third possibility, Route C, simply involves the stereospecific addition to the 
protonated double bond of (O4-18O)-14. 
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Figure 6: Three possible mechanisms of the tocopherol cyclase catalyzed ring-         
                 closure. 
 
Route A is distinguished from Routes B and C by the elimination of the phenolic 0-
atom and Routes B and C are distinct with respect to the configuration at C(3) of 1, if 
the incubation of (O4-18O)-14  is done in deuterated buffer. To analyse the incubation 
product, it was necessary to synthesise derivatives of the two cyclisation products 
(3R)-(3-2H)-3 and (3S)-(3-2H)-3. Spectroscopic comparison of the two synthetic 
products with the corresponding compound of enzymatic origin revealed that 
tocopherol cyclase operates by si-protonation of the double bond of 14 followed by 
re-attack of the phenolic O-atom to yield γ-tocopherol (3) (Route C in figure 6). This 
means that the reaction mechanism clearly requires an acidic residue for catalysis. 
 
This hypothesis involving a concerted, nonsynchronous cyclisation, during which 
positive charge develops at the carbon atom that is trapped by the phenol, is 
supported by the following two observations (figure 7):  
(1) The transition-state analogue tetrahydroisoquinolinium terpenoid 17 (figure 7) 
was designed so that the positive charge is placed near to the position which 
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corresponds to the double bond in the natural substrate 14. Binding studies 
showed that compound 17 is an excellent inhibitor (IC50 = 1.4 nM) of 
tocopherol cyclase.52    
(2) It could be shown, that the epoxide of 14 cyclises under acidic conditions 
affording two compounds, the five-membered ring “Baldwin” product and the 
favored six-membered ring  analogue of the enzymatic product.53   
 
 
Figure 7: The reaction mechanism of ring closure catalyzed by tocopherol cyclase.      
                 ES = enzyme-substrate; EP = enzyme product.54 
 
 
1.1.6 A Biomimetic Chromanol Cyclisation 
 
The first biomimetic chromanol cyclisation has been investigated in the group of 
Woggon54 and this concept involves:  
(1) The modification of 14 by attaching a chiral acid at the unsubstituted aromatic 
position (C(6)) and by introducing a bulky substituent through derivatization of 
the phenolic OH group at C(1) in order to restrict conformational freedom of 
this acid. 
(2) The choice of a suitable chiral acid. 
(3) The removal as well as the recovery of the chiral unit after cyclisation and 
determination of the product on an α-tocopherol derivative.  
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First biomimetic cyclisation studies were performed with prolinyl phytylhydroquinone 
derivatives 18 and 19 in the presence of either Lewis or BrØnsted acids. Cyclisation 
products 20 and 21, could be isolated, and subsequently converted into α-tocopheryl 
camphanate 22 (figure 8). The diastereomeric excess (de) was determined by HPLC, 
and a maximum value of 35 – 40% de was obtained in favour of the S-configuration 
at C(2). It seemed that the acidity of the chiral unit had no big influence on the 
reaction rate, yield, and de value. Therefore it was concluded that systems 18 and 19 
were too flexible and the distances between the acids and the double bonds were too 
large.  
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N NMe H
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O R
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O R
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Figure 8:  Biomimetic chromanol cyclisation of 18 and 19.  
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Consequently, cyclisation precursor (-)-(S,S)-23, possessing a more-rigid proline-
aspartate acidic spacer, was synthesised. Cyclisation in the presence of pTsOH 
yielded (-)-(2S,4’R,8’R)-22 with an improved de value of 80% (figure 9).  
 
In order to obtain the R-configuration at C(2), the S-configured amino acids and the  
(-)-camphanate in 23 were replaced by their enantiomers to give (+)-(R,R)-24. 
Cyclisation of the latter occurred in the presence of pTsOH to yield the natural 
(2R,4’R,8’R)-α-tocopherol (1) as the dominant diastereomer with 70% de (figure 9).  
 
These results imply that the attachment of a proline-aspartate unit to a phytyl-
hydroquinone creates an enzyme-like conformation of the cyclisation precursor 
allowing diastereoface-selective preferential protonation of the double bond and 
concomitant attack of the phenolic oxygen atom. 
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Figure 9: Cyclisation of (-)-(S,S)-23 and (+)-(R,R)-24. 
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1.1.7 Industrial Synthesis of “Vitamin E” 
 
The industrial importance of this group of compounds is based on their biological and 
antioxidant activity.55 The determination of the vitamin E activity by the fetal 
resorption-gestation test in rats shows that (2R,4’R,8’R)-α-tocopherol (1) has the 
highest value of the eight naturally occurring compounds 1 – 8 (Figure 1) and also of 
its eight stereoisomers.57, 58  Due to its prominent biological activity most efforts have 
been directed to (2R,4’R,8’R)-α-tocopherol (1). But despite the rapid advances in 
stereoselective synthesis and the considerable efforts in approaches to this product, 
no economic commercial total synthesis of naturally identical (RRR)-α-tocopherol (1) 
could be realized until today.56  
 
Although biologically less active than natural (RRR)-α-tocopherol (1),57, 58 all-racemic-
α-tocopherol [(all-rac)-1], an equimolar mixture of all eight stereoisomers, is 
industrially the most important product, manufactured in about 35,000 tons per year 
worldwide, mainly applied as its acetate derivative.59 
 
The first synthesis of (all-rac)-1 (“synthetic vitamin E”) was carried out as an acid 
catalyzed condensation reaction of all-racemic isophytol (25) with trimethyl-
hydroquinone (26)60, 61 which resulted in the first Vitamin E production at F. 
Hoffmann-La Roche in the early 1950s (figure 10). 
 
OH
HO
OH
2526
acid
-H2O
HO
O
all-rac-1  
Figure 10: Industrial synthesis of all-racemic-α-tocopherol (all-rac-1). 
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Several classical Lewis and BrØnsted acids, or combinations thereof, work well in 
this reaction. Typical examples are ZnCl2/HCl, BF3, or AlCl3, applied in various 
organic solvents. Until today a large number of new catalysts and new reaction 
conditions have been developed in order to find environmental friendly and more 
efficient procedures. Examples of novel catalysts are clays, ion exchange resins, rare 
earth and indium metal halides and triflates, heteropolytungsten acids, various 
polyfluorinated compounds (imides, methides), and boron and phosphorous 
compounds.59  
 
The second form of industrially produced “vitamin E”, about 10% of the total amount, 
is isomerically pure (2R,4’R,8’R)-α-tocopherol (1), which is obtained by enrichment 
and purification of mixtures of tocopherol homologues 1 – 4 from soybean deodorizer 
distillates. To increase the value of the vitamin E concentrate, the lower β-, γ-, 
δ-homologues 2 – 4 have to be converted to the biologically more active α-tocopherol 
(1) (only ca. 5% in the original mixture) by permethylation with subsequent 
reduction.59 As permethylation methods, the halo-,62 the amino-,63 or the 
hydroxymethylation64 reaction are employed. An example of an aminomethylation of 
δ-tocopherol (4) with subsequent hydrogenation is shown in figure 11.65 
 
HO
O
morpholine
CHO
4
HO
O
N
N
O
O
27
H2 (50 bar),
Pd / C, 100 °C
HO
O
1  
Figure 11: Aminomethylation of δ-tocopherol (4) to α-tocopherol (1).66 
 
The unsubstituted aromatic positions are aminomethylated via a Mannich-reaction 
with morpholine and formaldehyde to yield Mannich-product 27. Removal of the 
morpholine-groups by hydrogenation gives the desired α-tocopherol (1). The two 
Introduction 
 - 17 -   
forms of α-tocopherol (1) (or their acetate derivatives) are produced for applications 
in animal feed, food or the pharma and cosmetic industries. 
 
 
1.1.8 First Total Synthesis of SRR- and RRR-α-Tocopherol  
 
The first synthesis of RRR-1 and SRR-1 was published by Mayer et al. in 1963.67 All 
other approaches, which had been described in the literature until then, had given the 
C(2)-racemic product with trimethylhydroquinone and natural phytol as starting 
materials. The problem of generating the right configuration at C(2) was solved by 
optical resolution. The synthetic pathway for the chroman building block is depicted in 
figure 12.  
HO
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COOH
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O
AcO
COOCH3
O3
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26 28
29
30
31
32
rac-33
3435
36
37 R-33  
Figure 12: Synthetic pathway of chroman building block R-33. 
 
Trimethylhydroquinone (26) was converted to the benzaldehyde 28 via a Duff-
reaction.68, 69 Acetylation and reaction with compound 29 gave the α,β-unsaturated 
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ketone 30, which was hydrogenated to the saturated ketone 31. A Grignard-Reaction 
with ethynylmagnesium bromide gave the corresponding alcohol which could cyclise 
to the chroman-ring after acidic removal of the acetate protecting groups. The free 
phenol was reprotected with acetic anhydride to yield compound 32. A carboxyl-
group was introduced through reaction of deprotonated 32 with CO2 to afford 34. The 
key step of the synthesis is the separation of the enantiomers of acid 34, which was 
achieved via optical resolution of the corresponding quinine salts to give optically 
pure 35 as well as the S-enantiomer. Partial catalytic hydrogenation employing the 
Lindlar-catalyst yielded compound 36. Esterification with MeOH followed by 
acetylation gave compound 37, which was converted to the isomerically pure building 
block R-33 by ozonolysis. 
 
The second building block, the C15-component 43, was obtained by degradation of 
natural (2E,7R,11R)-phytol 38 as shown in figure 13.  
 
HO
38
H+
and cis- and trans isomers39
O3
O
H
40
LiAlH4
HO
41
HBr
Br
42
P(C6H5)3
(C6H5)3P
Br
43  
Figure 13: Synthesis of the building block 43. 
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The aldehyde R-33 was coupled with the phosphonium salt 43 by a Wittig reaction. 
This was followed by the reduction of the coupling product 44 to give RRR-α-
tocopherol (figure 14). 
  
O CHO
AcO
R-33
(C6H5)3P
Br
43
1) LiC6H5
2) Ac2O
O
AcO
44
1) H2
2) LiAlH4
O
HO
1  
Figure 14: Final steps of the synthesis of RRR-α-tocopherol.  
 
In the proceeding years, many of synthetic schemes have been employed for the 
stereoselective synthesis of isomers of α-tocopherol (1), in particular RRR-1.59 Four 
general strategies have been followed: 
(1) Classical optical resolution delivers mainly chroman building blocks.  
(2) Biocatalysis (by microorganisms and isolated enzymes) gives access to chiral 
intermediates. 
(3) Asymmetric catalysis opens the way to a variety of products. 
(4) Chiral pool starting materials and chiral auxiliaries in stoichiometric amounts 
are also applied. 
For large scale applications, many of those methods suffer from complexity, limited 
space-time yield, and formation of excessive amounts of waste material, which is the 
reason why an economic industrial synthesis of RRR-1 hasn’t been found until today. 
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1.1.9 A Short Route to α-Tocopherol 
 
Recently Woggon et al. reported a synthesis of α-tocopherol (1) in which an 
organocatalyst was applied for the first time to the construction of chromanols 
(figure 15).70 
 
Phytenal (46) was reacted with ortho-hydroxy aldehyde 4571 by using proline-derived  
organocatalyst 47 to yield hemiacetal 48, which was subsequently oxidised to lactone 
49 with a de value of 97%. Hydrogenation of 49 afforded acid 50, which could be 
converted to the α-tocopherol ether 51 by using a Barton decarboxylation 
procedure.72 Ether 51 was cleaved by treatment  with BF3·Me2S/AlCl3 to yield 
RRR-α-tocopherol (1) in an overall yield of 29% and with a 93% diastereomeric 
excess. 
 
The proposed reaction mechanism of the formation of 48 is depicted in figure 16. 
The iminium salt 52 produced initially leads to dieneamine 53, which reacts with 
salicylaldehyde (45) to yield the intermediate 54 via an aldol reaction. Compound 54 
then cyclises diastereoselectively in an intramolecular oxa-Michael addition to give 
lactol 48. The aldol reaction is the key step that controls the stereoselectivity of the 
formation of the syn arrangement of the six-membered lactol. 
 
This synthetic strategy can potentially be applied to the synthesis of other members 
of the vitamin E family, as well as to other natural products containing highly 
substituted, chiral compounds.  
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Figure 15: Synthesis of (RRR)-α-tocopherol via a domino aldol/oxa-Michael reaction. 
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Figure 16: Proposed mechanism for domino aldol/oxa-Michael reaction leading to 
                  lactol 48.  
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1.2 Supramolecular Chemistry and Enzyme Mimetics 
 
1.2.1 What is supramolecular chemistry? 
 
Jean-Marie Lehn, one of the protagonists in the field of supramolecular chemistry 
gave the following definition:73  
 
“Supramolecular Chemistry can be defined as chemistry beyond the 
molecule, referring to the organised entities of higher complexity that 
result from the association of two or more chemical species held 
together by intermolecular forces.”  
 
The area of supramolecular chemistry has grown exponentially in the last few 
decades and therefore this broad, loose description is indeed rather accurate to 
encompass all subjects related to this area. It is a highly interdisciplinary field, 
extending over organic chemistry, coordination chemistry, physical chemistry and the 
experimental/theoretical studies of interactions. Thus, supramolecular chemistry 
provides the link between physics, chemistry and biology and enables the study and 
understanding of very large molecular assemblies. 
 
Both intermolecular and intramolcular forces play a crucial role in the organization of 
large molecular assemblies. In particular, noncovalent interactions, such as Coulomb 
forces, hydrogen bonding, Van Der Waals- and hydrophobic interactions are of great 
importance. These noncovalent interactions are regarded as the basis of many 
biological processes such as receptor-ligand binding, enzyme-substrate complex 
formation, antibody-hapten binding, and cell surface recognition. Therefore 
supramolecular chemistry has provided, and will continue to provide an insight into 
the process of self-organisation of artificial synthesizable molecular assemblies. 
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1.2.2 Cyclodextrins 
 
1.2.2.1 Molecular Structure and Chemical Properties 
 
Cyclodextrins (CD’s) are a family of natural and synthetic cyclic oligosaccharides 
containing α-1,4-linked glucopyranose units (figure 15). They were first discovered in 
1891 by A. Villars,74 and later the naturally occurring CD’s were identified.75 The α-, 
β- and γ- CD’s are all of industrial importance containing six, seven and eight glucose 
units respectively. However, it is the β-CD which is produced on the largest scale.76, 
77, 78 
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Figure 15: Left: The structure of β-CD; right: 4C1-conformation of glucose unit in  
                 β-CD. 
 
The glucopyranose units of β-CD (55) are in a 4C1-conformation resulting in all 
primary hydroxyl groups oriented to the outside of the ring. The diameters of the 
upper and lower faces of the CD differ in size and the structure is more accurately 
described as a conical cylinder or more commonly referred to as doughnut-shaped or 
a bottom-less bowl (figure 16).   
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Figure 16: Doughnut shape icon of CD illustrating the size and dimensions of β-CD 
                 (55) 
 
The molecular orientation of the conical-cylinder leads to a polar outer-surface and 
the potential to form hydrophilic interactions. Contrastingly, the cavity is considerably 
less hydrophilic due to the axial-hydrogen atoms and glycosidic oxygen atoms 
pointing to the interior of the molecule. This solubility gradient provides a water 
soluble exterior with a hydrophobic cavity enabling inclusion of a range on guest 
molecules.  α-, β- and γ-CD molecules have a different number of glucose subunits 
and therefore differ in size and the cavity diameter. The diameter of β-CD’s 
hydrophobic cavity is 7.8 Å and allows inclusion complex formation with various 
guest molecules. The diameters of α- and γ-CD will enable selective inclusion of 
guests of different sizes (Table 2).     
 
Cyclodextrin Mass Outer diameter
(nm) 
Inner diameter 
(nm) 
Solubility 
H2O (g/kg) 
α 972 1.37 0.57 129.5 
β 1134 1.53 0.78 18.4 
γ 1296 1.69 0.95 249.2 
 
Table 2: The properties of α-, β- and γ− cyclodextrin.79 
 
The binding constants of inclusion complexes of aromatic (56, 57, 58, 60) and 
aliphatic (59) compounds with CD’s are shown in table 3.80 Structures containing a 
tert-butyl- or adamantyl-rest show especially good binding affinities. Non-covalent 
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interactions, such as hydrogen bonds, dipole-dipole, Van Der Waals- and 
hydrophobic interactions, are of paramount importance and are considered as the 
driving-force of complex formation. The large variety of guest molecules available for 
complex formation makes CD’s attractive subjects for supramolecular chemistry. It’s 
noteworthy that intermolecular interactions (~0.5-5 kcal/mol) are about an order of 
magnitude weaker than covalent chemical bonds (~40-250 kcal/mol). Consequently, 
many non-covalent interactions are required in CD-inclusion-complex formation. 
  
Compound α-CD β-CD γ-CD 
benzoic acid (56) 16 M-1 23 M-1 3 M-1 
4-methylbenzoic acid (57) 36 M-1 66 M-1 8 M-1 
4-tert-butylbenzoic acid (58) 51 M-1 457 M-1 59 M-1 
1-adamantanecarboxylic acid (59) 114 M-1 501 M-1 42 M-1 
Ibuprofen (60) 55 M-1 2600 M-1 59 M-1 
 
Table 3: Inclusion complex formation constants of CD’s with various guest molecules 
 
Unmodified CD’s have fairly rigid structures, due to intramolecular hydrogen bonds 
between C(2)-OH and C(3)-OH of adjacent glucose units.81  
 
To summarise, the following chemical and physical properties make CD’s attractive 
components for substrate-recognition moieties in enzyme models and catalysis:82  
 
(1) High water solubilities. 
(2) The hydrophobic cavities can accommodate a wide variety of guest molecules. 
(3) Their structures are well defined due to intramolecular H-bonds. 
(4) “Facile” functionalisation of the hydroxyl groups provides a variety of catalytic 
residues. 
(5) CD’s are chiral and can therefore be used in asymmetric catalysis. 
 
CD’s are industrially produced from starch by an enzymatic reaction with cyclodextrin 
glucosyl transferase (CTG), which can be isolated from several bacteria like Bacillus 
macerans, Klebsiella oxytoca or Bacillus circulans.80 In this process a complicated 
mixture of several cyclic and linear oligosaccharides is produced. This mixture can be 
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purified by addition of an appropriate complex forming agent (e.g. toluene for the 
isolation of β-CD), filtration and crystallization. Several 1000 tons of CD’s are 
produced per year. They are widely used as additives in pharmaceuticals, food and 
cosmetics, as well as in analytical chemistry (e.g. separation of enantiomers by chiral 
HPLC).80  Since β-CD is the cheapest of the cyclodextrins, and its cavity has an ideal 
size to host a broad range of substrates, it has been used most extensively and the 
following chapters will focus solely on β-CD-examples.  
 
 
1.2.2.2 Cyclodextrin Based Enzyme Mimics 
 
It has been shown that modification of CD’s may not be necessary for the 
development of enzyme mimics. It should be noted that not all CD-based enzyme 
mimics have prosthetic groups attached to the CD moiety. Breslow showed in 1983 
that unmodified β-CD accelerates the hydrolysis of various esters at pH 10.83  This is 
a result of the proximity effects existing in intramolecular processes and enzyme-
substrate species. Ester 62 hydrolyzes 3.2 x 106 times faster in the presence of β-CD 
(figure 17). Interestingly, one of the two enantiomers reacts 20-fold faster than the 
other one. The stereoselection may be explained by the fact that β-CD forms a 
stronger inclusion complex with one of the two enantiomers. β-CD-oxyanion 61 
attacks the carbonyl group of the ester producing acylated β-CD 63 and 
p-nitrophenolate 64. It is noteworthy, that this reaction is not catalytic, but can be 
considered as a first imitation of an enzymatic reaction (esterase) due to the 
attractive properties of β-CD.  
 
β β
Fe
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Figure 17: Hydrolysis of esters with CD-oxyanion 61 
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Highly sophisticated enzyme mimics can be obtained by attaching catalytic groups to 
CD. Breslow was also the first to report the synthesis of multi-component systems by 
attaching known catalysts for oxidations, namely metallosalens and metallo-
porphyrins, to CD’s.84 In order to mimic the selectivity of enzymes, artificial receptors 
65 – 68 (figure 18) were prepared. 
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Figure 18: Structures of CD- receptors 65 – 68. 
 
Artificial CD-receptors were developed and designed to optimise the binding affinity 
enabling binding into two CD-moieties of the same receptor (65, 66, 68). This was 
accomplished by carefully choosing substrates with the ideal size and geometry.  The 
stilbene derivate 69 was employed in order to test metal complexes 65 – 68 in the 
selective, competitive epoxidation.  In contrast, stilbene derivative 70 was chosen as 
a “worse fitting” substrate after initial binding studies (figure 19). Iodosylbenzene was 
employed in the formation of the manganese oxo group of catalysts. The selectivity 
of the epoxidation could be improved upon the addition of adamantanecarboxylate up 
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to a certain concentration when porphyrin catalysts 65 and 66 were employed. The 
role of adamantanecarboxylate can be regarded as a face protection agent. The 
substrate (69 or 70) binds to the catalyst (65 or 66) on one face of the porphyrin, 
leaving the possibility that the oxo group goes to the second face to perform 
nonselective oxidation of substrates. However, adamantanecarboxylate coordinates 
and blocks the second face thereby preventing nonselective oxidation. Interestingly, 
substitution of adamantanecarboxylate with a smaller group, such as acetate, 
resulted in no such face selectivity and consequently the selectivity of the reaction 
was reduced (figure 20).  
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Figure 19: The reactions of ideal and ‘worst case’ stilbene residues with catalysts 65 
– 68. 
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Mn
O
O
O  
Figure 20: A schematic representation of a substrate binding into two CD receptors 
of a Mn(V)porphyrin. The Mn carries an oxygen that will add to the substrate double 
bond, and the opposite face is shielded by adamantanecarboxylate.84 
 
Previously salen complexes have been employed as selective epoxidation 
catalysts.85 However, bis cyclodextrin catalyst 68 incorporating the salen moiety 
showed almost no selectivity between different substrates. In contrast, catalysts 65 
and 66 displayed an oxidation selectivity of up to 50-fold for the epoxidation of 69 
relative to 70. As was predicted, catalyst 67 showed poor selectivity.  This evidence 
supported the proposed binding geometry in the epoxidation reactions with catalysts 
65 and 66 in which the substrate spans over the porphyrin ring. 
 
The catalytic capabilities of porphyrin linked CD systems were further improved 
through the selective catalytic hydroxylation of a steroid derivative by a cytochrome 
P-450 enzyme mimic.86, 87, 88 Thus, CD-tetramer 65 (10 mol%) was incubated with 
derivatised steroid 73 in water for 2h with PhIO as the oxygen source (figure 21). 
40% conversion of 73 was observed after ester hydrolysis and quantification of the 
triol 74. The regioselectivity of the reaction was shown to be complete. The reaction 
was also stereospecific, yielding only the equatorial C(6)-alcohol. The catalyst was 
capable of only 4 turnovers before being oxidatively destroyed. 
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Figure 21: Regioselective hydroxylation of steroid 73 by a cytochrome P-450 
mimic.86 
 
The system was further improved by increasing the stability and reactivity of the 
catalyst through the introduction of fluorine to the free aromatic positions of the 
porphyrin linker (β-CD-tetramer 75 in figure 22).88 In contrast to 4 turnovers from 
catalyst 65, 75 was used in 1 mol% and gave 95% conversion of 73 to 74 (95 
turnovers). Unfortunately, the attempts to reduce the amount of catalyst employed 
were unsuccessful. Reaction with 0.1 mol% gave only 18.7% of product thereby 
indicating that at low catalyst loadings, product inhibition factors come into play. 
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 Figure 22: Improved cytochrome P-450 enzyme mimic. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 - 33 -   
1.2.3 β-CD based enzyme mimic of β,β-carotene-15,15’-moooxygenase: 
the essential contributions from “Woggon group”89, 90, 91, 92, 93, 94, 95, 96  
 
Many organic reactions have shown improved reactivity and selectivity with multi-
component, enzyme mimics based on CD.  Primarily, this is a consequence of the 
hydrophobic cavity of CD enabling it to behave as an “artificial receptor”.  
Additionally, dimer/tetramer systems of CD have been shown to be desirable in the 
cooperative binding and subsequent geometric control of specific substrates. Much of 
the focus has been on the catalysis of simple organic transformations and few of the 
complicated enzyme mimics have been devoted to the conversion of natural 
substrates to biologically important metabolites.  
 
Woggon et al. have succeeded in purifying an important enzyme from chicken’s 
intestinal mucosa. This enzyme has the ability to centrally cleave β,β-carotene. In 
contrast to earlier belief, further investigation has shown that this enzyme is not a 
dioxygenase but operates by a monooxygenase mechanism in which the first step is 
an epoxidation of the central C(15)-C(15’) double bond.  
 
An artificial supramolecular system, 76, was developed in parallel to the efforts to 
purify and investigate the native protein. The multi-component system 76, can mimic 
the enzymatic cleavage of carotenoids (figure 23).89, 90, 91, 92, 93, 95, 96 The structure of 
the enzyme mimic consists of two β-CD moieties linked via a ruthenium porphyrin on 
the primary face. Both of the terminal β-CD’s units are capable of binding one 
cyclohexenoid endgroup, either end of the β,β-carotene, leaving the porphyrin to 
span the polyene chain. It was estimated, based on computational calculations, that 
approximately half of β,β-carotene would be included in the β-CD cavities and that 
the critical C(15)-C(15’) double bond would be perfectly placed under the catalytic 
ruthenium centre.  
 
A biphasic system was required in order to apply this multi-component catalyst to the 
cleavage of β,β-carotene. β,β-Carotene was extracted into the water phase 
containing the catalyst 76 and cooxidant tert-butyl hydroperoxide (TBHP) from a 9:1 
mixture of hexane/chloroform. The products of the reaction were then released from 
the catalyst in the aqueous phase to the organic phase. Aliquots of the organic phase 
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were subjected to HPLC measure without workup. It was reasonable to conclude that 
this kind of biphasic system could efficiently avoid the product-inhibition effect. 
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Figure 23: Proposed binding mode of 76 and 77, and the cleavage result with TBHP 
as cooxidant.   
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The results indicate that 76/TBHP catalysed the cleavage of β,β-carotene at not only 
the central double bond (~40%) but also the excentric double bonds to yield 12’-apo-
β-carotenal 14 and 10’-apo-β-carotenal 10. It may be considered that the lateral 
sliding of β,β-carotene within the hydrophobic cavity of β-CD would result in the 
unselective cleavage. This hypothesis was proven by employing 17-nor-φ,β-carotene 
81 as substrate. The resulting cleavage was in fact very regiospecific as only retinal 
(78) and the corresponding fragment 82 were detected (figure 24). This suggested 
that the stronger hydrophobic interaction between the aromatic endgroup of 81 and 
β-CD decreased the mobility of the 1:1 inclusion complex thereby increasing the 
stability. The central double bond is therefore positioned centrally under the reactive 
ruthenium centre in contrast to the same system with β,β-carotene. 
 
81
O
78
76 / TBHP
O
82  
Figure 24: Selective central cleavage of 17-nor-φ,β-carotene 81. 
 
The initial step in the cleavage of the double bond is epoxide formation catalyzed by 
the active ruthenium-oxo porphyrin species. This is subsequently followed by 
ruthenium porphyrin/TBHP mediated fragmentation yielding the aldehydes as shown 
in figure 25.94, 96 
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Figure 25: Proposed catalytic cycle with TBHP as cooxidant.94, 96  
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2 Aims of this Work 
 
As already mentioned, nature has evolved an enzyme (tocopherol cyclase) which 
catalyses the stereospecific ring closure of certain phytylhydroquinone derivatives to 
tocopherols (figure 5). Mechanistic studies revealed that the chromanol ring 
formation involves a si protonation of the double bond followed by concomitant attack 
by the phenolic O-atom to give diastereomerically pure tocopherol (figure 26). 
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Figure 26: Enzymatic chromanol formation. 
 
Based on the mechanistic steps involved in this enzymatic chromanol formation, a 
novel short and efficient synthetic pathway for natural α-tocopherol (1) should be 
found. One way to imitate the transition state 83 would be by stereoselective 
epoxidation followed by cyclisation under acidic conditions (figure 27).  
 
The main problem to be solved within this work would be to find a catalyst that is 
capable of epoxidising alkene 84 with high diastereoselectivity and the correct 
configuration. It would therefore be of critical importance to find suitable protecting 
groups R and R’.  
 
Among others, novel cyclodextrin based catalysts should be synthesised and their 
catalytic properties investigated. 
 
Aims of this Work 
 - 38 -  
RO
OH
O
RO
O
RO
OH
O
RO
OR'
1) stereoselective epoxidation
2) removal of R'
H+
H
OH
84
 
Figure 27: Possible pathway for the formation of the chromanol moiety. 
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3 Results and Discussion 
 
3.1 Cyclodextrin Modified on Primary Face 
 
3.1.1 Attachment of a Tris(2-pyridylmethyl)amine (TPA) Derived Ligand to 
         β-Cyclodextrin 
 
It has been shown by Que et al. that iron complexes of tris(2-pyridylmethylamine) 
(TPA) and related ligands can be utilized as models of nonheme iron oxygenases 
and as catalysts for selective oxidative transformations of organic substrates 
(figure 28).97, 98, 99, 100 Evidence has accumulated suggesting that this chemistry is 
mediated by high-valent iron-oxo species,101 as well as the ability to induce 
asymmetry in certain products using chiral ligand derivatives.102 However, the 
mechanisms of these reactions vary depending on the added oxidant.101 In the 
particular case of tert-butyl hydroperoxide (TBHP), O – O bond homolysis was 
proposed, leading to tert-butoxy radical (tBuO•) and oxoiron(IV).101 Aliphatic C – H 
bond hydroxylation then occurs through sequential H-atom abstraction by tBuO• and 
recombination of the alkyl radical at oxoiron-(IV), so the metal-centred oxidant is 
utilized only indirectly. 
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Figure 28: Selected ligands used for the modelling of nonheme iron centres.103  
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Since iron complexes of TPA (84) type ligands have shown good reactivity in 
catalytic oxidations of various organic substrates, it was selected as a suitable 
complexing agent for the attachment to β-CD. For the functionalization of β-CD, 
monotosylated β-CD 85, which is commercially available, was chosen as the CD 
source. In order to be able to displace the tosylate of monotosylated β-CD 85, a 
suitable nucleophilic group would have to be incorporated into the TPA ligand. For 
this purpose an amino-function was introduced in TPA (84) to give amine 90, which 
then could be attached to β-CD via a nucleophilic substitution reaction with 85 to 
afford precatalyst 91. The synthesis of the CD-based ligand 91 is depicted in 
figure 29. 
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Figure 29: Synthesis of CD-ligand 91. 
 
The commercially available starting material 2,6-bis(hydroxymethyl)pyridine (86), was 
first subjected to a substitution reaction with HBr to brominate the hydroxyl groups to 
afford 2,6-bis(bromomethyl)pyridine in 53% yield. This was then reacted with 1.1 
equivalents of phthalimide potassium salt to give the monosubstituted product 88 in 
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44% yield. The low yield can be accounted for by the formation of doubly substituted 
sideproduct. Transformation of 88 by nucleophilic substitution of the remaining 
bromine atom with di-(2-picolyl)amine afforded the protected primary amine in 82% 
yield. Deprotection of 89 was performed by hydrazinolysis and gave the desired 
nucleophilic building block 90. The TPA linked β-CD 91, was produced by treatment 
of monotosylated β-CD 85 with a 25 fold excess of amine 90. The large excess of 
amine 90 was used in order to obtain full conversion to 91, which made the isolation 
process much easier. The reaction could be monitored by ESI-MS analysis. The 
exact mass of the modified β-CD 91 is 1435.5. Apart from the molecule ion 
m/z = 1436.1 [M+H]+, the mass spectrum also shows the peak for the sodium ion 
adduct [M+Na]+ at 1458.0 (figure 30).  
 
  
Figure 30: Positive ion mode ESI-MS spectrum of 91. 
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3.1.2 Application of the β-CD Linked Pentadentate Nitrogen Ligand 91 in   
         Catalytic Oxidation Reactions 
  
Selective and catalytic oxidations of organic molecules are amongst the most 
important technological processes in chemical industry. Chemical raw materials are 
principally hydrocarbons, alkanes in particular. Due to their intrinsically inert nature, it 
is difficult to oxidize alkanes in a controlled and selective manner.104 
 
High-valent metal-oxo species have been proposed as one of the active 
intermediates not only in biological metalloenzymes such as oxidases and 
oxygenases, but also in the oxidative transformation of organic compounds catalyzed 
by transition metal complexes.105, 106, 107  
 
In order to be able to use β-CD-modified pentadentate nitrogen ligand 91 as an 
oxidation catalyst, suitable metal complexes have to be formed first before they can 
be oxidized to the corresponding metal-oxo species by treatment with a suitable 
oxygen atom transfer oxidant. 
 
For the first experiments MnCl2 was chosen as the metal source, because 
manganese is widely used in catalytic oxidations. For example, it is the metal of 
choice in the asymmetric Jacobsen epoxidation with salen-catalysts.108 
 
This catalytic system was then initially tested in epoxidation reactions. 3-(4-tert-
Butylphenyl)-1-propene (92) was chosen as a substrate and synthesized following a 
published procedure.109 NMR studies with similar substrates have shown that tert-
butylphenyl-groups enter the cavity of β-CD.110 The manganese complex of 91 was 
formed in situ by stirring a solution of 91 together with 1 eq. MnCl2 in a 1:1 mixture of 
MeCN and H2O at room temperature. The complex formation could be monitored by 
ESI-MS analysis. After substrate 92 was added and the mixture was stirred for 
15 min at room temperature in order to preform the substrate-CD-complex. Iodosyl-
benzene was slowly added as a methanolic solution, probably resulting in the 
formation of a manganese-oxo species, which then in turn could epoxidize the double 
bond in 92 (figure 31). The epoxide 93 was obtained in 48% yield, however, chiral 
HPLC analysis revealed that the racemic product was obtained. 
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In a first control experiment, the catalytic reaction was run without CD-ligand 91 and 
in a second control experiment without MnCl2. In both cases no product 93 was 
formed. 
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Figure 31: Catalytic epoxidation of alkene 92. 
 
The low yield and the lack of chiral induction through the CD-moiety means this 
system is not useful for the diastereoselective epoxidation of protected phytyl-
hydroquinone substrates (84 in figure 27). 
 
In the next step the oxidation of alkanes was examined. In a first experiment 1-tert-
butyl-4-propylbenzene (94) was employed as a substrate. Attempts to oxidize 94 with 
iodosyl-benzene as an oxygen atom donor were unsuccessful. However if 20 eq. 
tert-butyl hydroperoxide (TBHP) were used instead, the expected in benzylic position 
oxidised products could be obtained in 68% and 2% yield for the corresponding 
ketone (95) and alcohol (96) respectively (figure 32). 
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Figure 32: Catalytic oxidations of benzylic positions. 
 
Control experiments without 91 and then without MnCl2 again showed no conversion 
of the starting material 94. 
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The oxidation of non-activated C-H bonds was then investigated. tert-
Butylcyclohexane (97) was employed as a substrate for this most challenging type of 
oxidations (figure 33). 
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Figure 33: Catalytic oxidation of non-activated C-H bonds. 
 
The substrate 97 was oxidised in the 4- and 3-position relative to the tert-butyl group, 
whereas the 2- and 1-position remained untouched. A large excess of TBHP (50 eq.) 
and a rather high catalyst loading (10 mol%) was necessary in order to obtain a total 
yield of 61% of oxidised products. Analysis of the products by chiral GC showed that 
ketone 98 was obtained as a racemate. 
 
These results show that the CD moiety itself is not enough to induce stereoselectivity 
in these catalytic reactions. In order to get stereoselectivity, a chiral ligand would 
have to be designed such that an attachment to CD would be feasible. 
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3.1.3 Design of a Novel CD-linked Salen Ligand  
 
The Jacobsen epoxidation allows enantioselective synthesis of epoxides from 
alkenes. In contrast to other asymmetric catalytic epoxidation methods, such as the 
Sharpless epoxidation111 (used for epoxidation of allylic alcohols), there are no 
additional functional groups required, which allows a broader substrate scope for the 
transformation. By using Jacobsen Mn-salen catalysts, epoxides with high stereo-
selectivity can be obtained from prochiral disubstituted cis-olefins, whereas other 
olefins, with a few exceptions, enable epoxide formation only with moderate 
stereoselectivities (figure 34). This fact is well explained by a side-on perpendicular 
approach of olefin to the manganese-oxo bond of the Mn(V) intermediate.112, 113 
Consequently this would mean that salen catalysts would be unlikely to give good 
diastereoselectivities in the epoxidations of protected phytyl-hydroquinone substrates 
(84 in figure 27). 
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Figure 34: Jacobsen epoxidation of olefins. 
 
There was the hope that attaching such salen ligands to β-CD might have a 
beneficial effect on the stereoslectivity of epoxidation reactions of challenging 
substrates. In order to be able to attach a salen moiety to β-CD, salen catalyst 98 
had to be modified by introducing a nucleophilic group without destroying the C2-
symmetry of the ligand. The replacement of the cyclohexane ring in 98 by pyrrolidine 
would give the previously synthesised salen ligand 99.114 The chiral salen ligand 99 
with a pyrrolidine backbone has the advantage that different groups and fragments 
can be readily tethered to the backbone of the ligand through the N atom of 
pyrrolidine.115 Therefore it was assumed that salen ligand 99 potentially could be 
attached to β-CD (figure 35).  
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Figure 35: Attachment of salen ligand 99 to CD. 
 
The synthesis of salen ligand 99 was carried out following published procedures 
(figure 36).116, 117, 118  
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Figure 36: Synthesis of salen ligand 99. 
 
Natural L-(R,R)-(+)-tartaric acid (101) was reacted with benzylamine to give imide 
102. The condensation reaction was complete when the appropriate amount of water 
was collected with a Dean-Stark apparatus. Reduction of the imide 102 gave the diol 
103, which then could be mesylated in nearly quantitative yield. Nucleophilic 
substitution of the mesylate groups by azide proceeded under complete inversion of 
configuration. The diazide 105 was first reduced to the corresponding diamine, which 
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subsequently reacted with aldehyde 106 to form the desired Schiff-base ligand 99. 
The attachment of 99 to β-CD was performed as shown in figure 35 and gave the 
CD-modified salen ligand 100 in 49% yield after reversed phase column 
chromatography. Refluxing of 100 together with Mn(OAc)2 in EtOH followed by the 
addition of LiCl and air oxidation afforded the corresponding Mn(III)-complex 107 in 
82% yield (figure 37). The mass spectrum of 107 shows only one peak at m/z = 
1703, which corresponds to [M – Cl-]+ (figure 38). To the best of my knowledge, 
compound 107 is the first example of a chiral salen complex, which is covalently 
attached to β-CD.   
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Figure 37: CD-modified salen catalyst 107. 
 
 
 
Figure 38: Positive ion mode ESI-MS spectrum of 107.  
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3.1.4 Catalytic Experiment with CD-catalyst 107 
 
Unfortunately, the solubility of catalyst 107 in H2O, MeOH, MeCN, DCM or mixtures 
thereof is very low, which limits its applicability drastically. The reason for this 
behaviour lies presumably in the different polarity properties within the compound. 
On the one hand, there is the very polar CD-moiety, which is soluble in polar solvents 
such as water, on the other hand there are four hydrophobic tert-butyl groups on the 
attached salen moiety. However, eventually one solvent system was found in which 
catalyst 107 was soluble. When N-methylmorpholine-N-oxide (NMO) was added to a 
suspension of 107 in DCM, a solution could be obtained. This system had previously 
been employed for the epoxidation of unfunctionalized alkenes with chiral 
(salen)Mn(III) catalysts and mCPBA as an oxidant.115 The combination of NMO and 
mCPBA leads to an unreactive adduct, which is capable of oxygen atom transfer 
mediated by (salen)Mn(III) complexes.119, 120  
 
The use of DCM as a solvent is generally not desirable for reactions with 
CD-catalysts as the driving force for inclusion complex formation with a hydrophobic 
substrate is much lower than in aqueous solvents. However, the mCPBA/NMO 
oxidant system with CD-catalyst 107 was tested in the epoxidation of 4-tert-
butylstyrene (108) (figure 39). 
 
O
DCM, 107, NMO, mCPBA, r.t., 2 h
108 109  
Figure 39: Catalytic epoxidation of 108 with CD-catalyst 107. 
 
The epoxide 109 was obtained in 62% yield and with 9% ee. The stereoselectivity of 
this epoxidation was even lower than the previous example in which it had been 
obtained with the corresponding salen complex 110 lacking the CD moiety employing 
the standard conditions for Jacobsen-epoxidations (figure 40). When catalyst 110 
together with bleach as oxidant and 4-phenylpyridine N-oxide as an axial ligand was 
used, epoxide 109 could be obtained in 50% yield and 30% ee. 
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Figure 40: Catalytic epoxidation of 108 with salen catalyst 110. 
 
The very low solubility of catalyst 107 in aqueous solvents, its rather difficult 
synthesis, its high molecular weight, and the low selectivity for the epoxidation of 108 
in DCM, limits the usefulness of catalyst 107 drastically.  
 
Attempts to synthesise more water soluble derivatives of catalyst 107, in which the 
tert-butyl groups would be replaced by ionic phosphonium or sulphate groups failed. 
 
For reasons of applicability, catalysts with less complicated structures had to be 
designed. The attention was drawn to simple organocatalysts, such as ketone 
catalysts for stereoselective epoxidation of alkenes.  
 
 
3.1.5 A CD-Modified Ketone Catalyst 
 
Dioxiranes are powerful oxidizing agents that can be generated in situ from the 
reaction of Oxone (KHSO5) or other oxidants with ketones. Dioxiranes are widely 
used for epoxidations, C – H bond oxidation, and heteroatom oxidation.121, 122, 123  
 
Wong et al. reported in 2003 the use of a CD-modified ketoester as a supramolecular 
catalyst for stereoselective alkene epoxidation.124 The CD ketoester 111 was 
prepared by functionalization of the primary hydroxyl rim of β-CD with pyruvyl 
chloride (112) (figure 41).  
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Figure 41: Synthesis of β-CD ketoester 111. 
 
The activity of catalyst 111 was explored by Wong et al. for asymmetric epoxidation 
of styrenes. The epoxidation of trans-stilbene with 111 is shown in figure 42. 
Treatment of trans-stilbene with 111 in H2O/MeCN = 1:1.5 afforded the 
corresponding CD inclusion complex. Subsequent addition of Oxone then 
transformed the keto group of 111 into the corresponding dioxirane which is capable 
of epoxidising the substrate in 99% yield and 31% ee. 
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Figure 42: Epoxidation of trans-stilbene with 111. 
 
This example shows that CDs can serve as chiral templates to mediate asymmetric 
epoxidation via inclusion complex formation with moderate enantioselectivity. 
 
In order to obtain higher enantioselectivities for the epoxidation of olefins, a chiral 
ketone would have to be attached to β-CD. For this purpose a commercially available 
chiral ketone, which can be readily attached to β-CD, should be found. 
(1S)-(+)-Camphor-10-sulfonic acid chloride (112) seemed to be a suitable starting 
material for the synthesis of a new CD ketone catalyst, because it is chiral and it can 
be easily attached to β-CD through its sulfonic acid chloride function. The synthesis 
of the new potential β-CD ketone catalyst 113 is shown in figure 43. 
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Figure 43: Synthesis of potential β-CD ketone catalyst 113. 
 
Reaction of β-CD and 112 gave product 113 in 56% yield. The reaction side product, 
the doubly substituted β-CD, and unreacted starting material could be removed by 
C18 reversed phase column chromatography. 
 
CD ketone 113 was subsequently tested as a catalyst for the epoxidation of trans-
stilbene. The reaction conditions were chosen according to Wong et al. (figure 42).124 
However, no conversion of trans-stilbene could be observed by TLC, even after a 
prolonged reaction time of 12 h instead of 1 h. The lack of reactivity of 113 is most 
likely due to the fact that the keto function in 113 is not activated, which makes the 
nucleophilic attack of the oxidant (Oxone), needed for dioxirane formation 
substantially slower compared to compounds that possess activated keto 
functionalities, such as 111. 
 
CD based catalysts appear to be economically unsuitable for stereoselective 
epoxidation of protected phytyl hydroquinones (84 in figure 27) for the following 
reasons: 
 
• The molecular weight of CDs is relatively high. Therefore CD-derived 
catalysts would not be atom economical, unless they are recoverable.125 
• Since the reaction products may also bind to CD, product inhibition factors 
come into play, making a high catalyst loading necessary.   
• Synthesis and purification of CD-derivatives can be difficult, time consuming 
and expensive as silica gel column chromatography often isn’t possible. 
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• The choice of solvents is often limited to aqueous solvent systems due to the 
high polarity of CDs. 
 
The reasons given above made it necessary to find a suitable, low molecular weight 
catalyst that is capable of epoxidising hydroquinones (84 in figure 27) in a highly 
diastereoselctive fashion and in good yields.  
 
Asymmetric epoxidation has attracted significant attention in the past two decades. 
The Sharpless epoxidation method is a powerful tool for the asymmetric epoxidation 
of allylic alcohols. As already mentioned, for the enantioselsctive epoxidation of 
unfunctionalized olefins, the chiral Mn-salen catalysts are effective for a variety of 
olefin types, particularly conjugated cis-olefins.  
 
For our purpose, however, we needed an effective method for asymmetric 
epoxidation of trisubstituted olefins (trans-olefins). We envisaged that chiral ketones 
could be ideal catalysts for this task.  
 
 
3.2 Organocatalytic Asymmetric Epoxidation of Protected Phytyl 
       Hydroquinones 84 by Chiral Ketones 
 
3.2.1 Introduction 
 
In recent years, chiral dioxiranes, generated from the corresponding ketones, have 
been shown to be powerful agents for asymmetric epoxidations of olefins, particularly 
for unfunctionalized trans and trisubstituted olefins, which has been a long-standing 
problem.126 When examining the features of trisubstituted and trans-disubstituted 
olefins, it is noticeable that both of them have one large and one small substituent on 
either one side or one terminus of the C – C double bond (figure 44). Under either a 
spiro or planar transition state (figure 45), chiral dioxiranes bearing large and small 
substituents, respectively, on each face of the dioxirane should have the potential to 
discriminate between the large and small groups on the C – C double bond. Hence, 
this could offer a promising solution to the problem of asymmetric epoxidation of 
hydroquinones 84. 
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Figure 44: Recognising olefin substitution patterns. 
 
There is evidence through experimental127 and computational128 studies that the spiro 
transition state is favored, presumably due to the stabilizing interaction of an oxygen 
lone pair with the π* orbital of the alkene in the spiro transition state (such an orbital 
interaction is not geometrically feasible in the planar transition state) (figure 45). 
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Figure 45: The spiro and planar transition states for the dioxirane epoxidation of 
olefins.129 
 
Since the first chiral ketone mediated epoxidation reported by Curci130 in 1984, a 
variety of chiral ketones have been investigated in a number of laboratories, and 
significant progress has been made in the field. Among the considerable advances in 
the search for efficient chiral ketone catalysts, the fructose-derived ketones 
developed by Shi and co-workers have proved to be the best ketone catalysts in 
chiral dioxirane epoxidation. For example, ketone 114, which is commercially 
available, or can be readily prepared from very inexpensive D-fructose by ketalization 
and oxidation (figure 46), gives the highest ee values for a broad range of different 
olefins. 
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Figure 46: Synthesis of the Shi ketone 114. 
 
In general, two different oxidants are used for the in situ generation of the 
corresponding dioxirane from ketone 114. The oxidant that is almost exclusively used 
for ketone-mediated epoxidations is Oxone (a commercial mixture of 2:1:1 
KHSO5:KHSO4:K2SO4) with potassium peroxomonosulfate (KHSO5) being the active 
component. Generally, the optimum pH for dioxirane epoxidation is 7 – 8. At higher 
pH, Oxone tends to decompose. However, at pH 7 – 8 the Shi catalyst 114 
decomposes due to a competing Baeyer-Villiger reaction. By increasing the pH to 
10.5 (by addition of K2CO3), the amount of Oxone can be reduced to a stoichiometric 
amount (1.5 eq.), suggesting that the high oxygen content of ketone 114 makes it 
sufficiently reactive to compete with Oxone decomposition. The proposed catalytic 
cycle is depicted in figure 47. 
 
In 1999 Shi et al. reported for the first time the use of hydrogen peroxide (H2O2) as 
an oxidant for the generation of dioxiranes from ketones.131, 132 Hydrogen peroxide 
(H2O2) is a particularly attractive oxidant due to its high active oxygen content with its 
reduction product being water. Studies have shown that a combination of hydrogen 
peroxide and a nitrile, used as a solvent, provides an effective system for epoxidation 
with a catalytic amount of ketone 114. However, when the reaction was carried out in 
other solvents, such as DMF, THF, DCM, EtOH, or dioxane without the addition of a 
nitrile, only trace amounts of epoxide were detected. This result suggests that 
hydrogen peroxide itself cannot effectively generate the dioxirane and that nitrile 
plays an important role. Hydrogen peroxide is likely to be activated by the nitrile (116) 
by forming peroxyimidic acid (117), which then reacts with ketone 114 to generate 
the dioxirane (figure 48). Out of a number of different nitriles tested, MeCN gave the 
best results in the asymmetric epoxidation of trans-β-methylstyrene with ketone 114 
and H2O2, in terms of conversion and ee.132 It was found that the H2O2-MeCN system 
provided similar enantioselectivities to Oxone. The catalyst loading is somewhat 
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substrate dependent and it can be reduced to as low as 10 mol% in some cases. 
Further studies showed that a mixed solvent such as MeCN-EtOH-DCM was 
beneficial for olefins with poor solubility. 
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Figure 47: Proposed catalytic cycle of the epoxidation by ketone 114 using Oxone as 
the stoichiometric oxidant. 
 
Analysis of the stereochemistry of the epoxides produced by the chiral dioxirane 115 
provided further understanding of the transition state involved in this reaction. The 
corresponding dioxirane 115 of ketone 114 has two diastereomeric oxygens, and the 
equatorial oxygen is likely to be sterically more accessible for olefin approach. 
Among possible spiro and planar transition states for the epoxidation with ketone 
114, spiro B – D and planar F – H are disfavoured by destabilizing steric interactions 
(figure 49). Spiro A and planar E are the two sterically favoured transition states. 
Experimental data show that spiro A is the predominant transition state with planar E 
being the major competing transition state. The extent of the involvement of planar E 
depends on the nature of the substituents on the olefin. Figure 50 shows that 
epoxidation via spiro A and planar B result in opposite configuration of the epoxide 
product, which consequently affects the ee of the product.      
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Figure 48: Proposed catalytic cycle of the epoxidation by ketone 114 using hydrogen 
peroxide as the stoichiometric oxidant. 
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Figure 49: Possible spiro and planar transition states for the epoxidation for the 
epoxidation with ketone 114. 
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Figure 50: Competing spiro A and planar E transition states for the epoxidation with 
ketone 114.  
 
With regard to the steric effect, generally higher ee values can be obtained by 
decreasing the size of R1 (favouring spiro A), increasing the size of R3 (disfavouring 
planar E) or both. The experimental data that supports this assumption is given in 
figure 51.133  
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Figure 51: Steric effects that influence the ee of the epoxides obtained by ketone 
114 mediated epoxidation.133 
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3.2.2 Synthetic Strategy for the Synthesis of α-Tocopherol via Shi 
         Epoxidation According to Figure 27 
 
In our approach for the synthesis of α-tocopherol, the key step is the asymmetric 
epoxidation of protected phytyl hydroquinone derivatives 84. The only possibility of 
influencing the de value of the epoxidation is to change the size of R3 by choosing 
different protecting groups R and R’, whereas R1 and R2 cannot be changed 
(figure 52). However, the fact that the alkyl chain R1 is rather big, probably makes the 
task to obtain high de values in the asymmetric Shi epoxidation of 84 very 
challenging (see examples in figure 51).  
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Figure 52: The structural properties of protected phytyl hydroquinone derivatives 84, 
which play a role in the asymmetric Shi epoxidation of 84. 
 
In order to obtain the chroman moiety in the right configuration by epoxide opening in 
a SN2 fashion following the reaction path shown in figure 27, the epoxide of 84 would 
have to be formed with an (S,S)-configuration. By analysing the expected transition 
state (spiro A in figure 49) for the epoxidation of 84 with commercially available 
D-fructose derived Shi catalyst 114, the undesired (R,R)-configuration would have to 
be expected. This would make the synthesis of the enantiomer of 114 necessary, 
which can be prepared from readily available L-sorbose in 5 steps.  
 
In a first step some epoxidation precursors 84 would have to be synthesised and 
tested in the asymmetric Shi epoxidation with the commercially available catalyst 
114, in order to see whether good diastereoselectivities can be obtained for the 
corresponding epoxides and to elucidate their actual configuration.  
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3.2.3 Asymmetric Shi epoxidation of protected phytyl hydroquinone 
         derivatives 84 
 
As a starting point the epoxidation precursor 118, which was available in our lab and 
had been synthesised by Julien Chapelat, was subjected to the Shi asymmetric 
epoxidation conditions (figure 53). It should be noted that 118 differs from 84 by the 
lack of a methyl group on the aromatic ring, which would give γ-tocopherol (3) in the 
end. Hydrogen peroxide was chosen as the primary oxidant and a mixture of 
MeCN:EtOH:DCM (1:1:2) was used as a solvent together with 2 M K2CO3 in 4 x 10-4 
M EDTA as a buffer, since this system had proven to be beneficial for olefins with 
poor solubilities and allowed easy handling, also for small scale reactions. 
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 Figure 53: Shi epoxidation of 118. 
 
Analysis of the product by chiral HPLC gave a de value of 65% for epoxide 119, 
which is far below the desired >90%. However, there was hope that the 
stereoselectivity of the reaction could be improved by the right choice of the 
protecting groups for the hydroquinone moiety. Further investigations done by Julien 
Chapelat revealed that, it is possible to cyclise 119 under acidic conditions yielding 
the desired 6-membered ring as the major product. As expected, comparison of the 
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cyclised product with an authentic sample suggested that the epoxide 119 was 
obtained in the wrong (R,R) configuration.  
 
Accordingly, a number of bis-protected phytyl hydroquinones 84 were prepared in 
order to optimize the diastereoselectivity of the asymmetric Shi epoxidation. 
 
In all syntheses, the phytyl chain was introduced via phytyl bromide (126), which was 
prepared by bromination of phytyl alcohol (127) (figure 54). 
 
Br
OH
127
126
PBr3, THF
      98%
 
Figure 54: Synthesis of phytyl bromide (126). 
 
The synthetic pathway for the synthesis of bis-protected phytyl hydroquinones 121, 
124 and 125 is depicted in figure 55. MOM bis-protected hydroquinone 120 was 
obtained from the reaction of trimethyl hydroquinone 26 and MOMCl using NaH as a 
base in DMF. The coupling of 120 with 126 involved the directed lithiation of 120 with 
butyl lithium in ether followed by the addition of a catalytic amount of anhydrous CuBr 
to form the corresponding cuprate  species, and the addition of phytyl bromide (126). 
After stirring for 4 h at r.t. the desired coupled product 121 was obtained in 64% yield. 
The cleavage of the MOM ethers was achieved by an oxidative cleavage method 
with cerium ammonium nitrate in a mixture of MeCN and water. The product, quinone 
122, was formed within 1 h in 85% yield. The reduction of quinone 122 to the 
corresponding hydroquinone 123 was performed using sodium dithionite in a mixture 
of THF and water. After brief workup, owing to the sensitve nature of the product, 
hydroquinone 123 was taken directly without further purification for the bis-protection 
steps using either TIPSCl or DPSCl to obtain the epoxidation precursors 124 and 
125, respectively. 
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Figure 55: Synthesis of bis-protected phytyl hydroquinones 124 and 125. 
 
In a different approach further substrates for the Shi epoxidation were prepared 
(figure 56). Trimethyl hydroquinone was reacted with MeI to afford monomethylated 
product 128 in 53% yield. It turned out that the remaining free hydroxyl group in 128 
is less reactive and therefore only a small amount of its regioisomer apart from the 
doubly substituted compound was formed. Reaction of phytyl bromide (126) with 
mono-protected hydroquinone 128 gave 129 in 92% yield. A lewis acid mediated 
Claisen-type rearrangement of 129 in the presence of BF3·Et2O gave rearranged 130 
within 10 min at -30 °C in 69% yield.134, 135 The main product was obtained with an E-
configured double bond (130). As a side product the Z-alkene isomer of 130 was also 
formed in about 15 to 20% which made a separation of the E / Z-mixture by flash 
chromatography on silica gel necessary. Since the two isomers could not be 
separated completely on TLC, the purity of the fractions had to be carefully analysed  
by 1H-NMR (figure 57). The content of the Z-isomer was in any case less than 3%, 
which is about the amount of Z-isomer present in phytyl alcohol 127 used as a 
starting material. The free hydroxyl group could be protected by reaction with either 
benzyl bromide to give 131, with tert-butyl(diphenyl)silyl chloride (DPSCl) to afford 
132 or with chloro(tribenzyl)silane to yield 133.    
 
 Results and Discussion 
 - 62 -  
HO
OH
MeI, NaH, DMF
0 °C, 53%
O
OH
26
R
Br
126
, NaH,
  DMF
0 °C, 92%
128
O
O R
129
BF3 Et2O,
DCM, -30 °C
69%
O
OH
130
R
benzyl bromide,
       NaH, DMF,
               0 °C, 78%
O
O
131
R
DPSCl, NaH, 
DMF, 0 °C, 
83%
O
O
132
R
Si
chloro(tribenzyl)silane,
     NaH, DMF, 0 °C
         80%
O
O
133
R
Si
 
Figure 56: Synthesis of epoxidation precursors 131, 132, 133. 
 
Swenton et al. reported that trimethylhydroquinone (26) can be monoprotected 
regioselectvely at the sterically less hindered hydroxyl function by tert-butyl- 
(diphenyl)silyl chloride (DPSCl).136 This reaction was used for an alternative synthetic 
pathway for 132 (figure 58). The monoprotected intermediate 134 was reacted with 
126 to give the coupling product 135. The Lewis acid mediated Claisen-type 
rearrangement of 135 in the presence of BF3•Et2O, to our surprise, worked also well 
for this case. However, the separation of the E / Z mixture of 136 was a lot more 
difficult than the one for 130. On TLC, there was no difference in Rf value. Separation 
could be achieved by flash chromatography, using a very long column and by 
analysing each fraction by HPLC. Methylation of the remaining free hydroxyl afforded 
132 again. 
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Figure 57: Section of the 1H-NMR spectrum of 130 
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Figure 58: Alternative synthesis of 132. 
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In order to be able to form the chromanol ring with R-configuration at C(2) by epoxide 
opening as shown in figure 27, the enantiomer of the D-fructose derived Shi catalyst 
114 had to be prepared. In 2006 Shi et al. reported a synthesis of the enantiomer of 
114, which involves the preparation of L-fructose from readily available L-sorbose 
(figure 59).137 Ketalization of pulverized L-sorbose gave katal 137, which was used 
directly for mesylation to give mesylate 138 in 37% yield over two steps after 
recrystallization. The transformation of mesylate 138 to L-fructose could be achieved 
via deprotection of the 4,6-O-isopropylidene group of 138, which could be easily 
done using 4.5% H2SO4 at room temperature for 3 h to give diol 139. After the 
solution became alkaline using 9 M NaOH, the conversion of compound 139 to 141 
via epoxide 140 can be efficiently achieved at 90 – 100 °C in 8 h. The 
1,2-O-isopropylidene group of triol 141 was then easily removed to give a syrup from 
which L-fructose was obtained by extraction with hot ethanol. The crude L-fructose 
was directly ketalized with dimethoxypropane and H2SO4 in acetone to give alcohol 
142 in 38% overall yield from mesylate 138. The oxidation of alcohol 142 with PDC 
gave ketone ent-114 in 82% yield.     
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Figure 59: Synthesis of L-fructose-derived Ketone ent-114. 
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With catalyst ent-114 in hand the asymmetric Shi epoxidations of the synthesised 
bis-protected phytyl hydroquinones were carried out (figure 60). Alkene-substrates 
143, 144, 145 and 146 for asymmetric Shi epoxidation were synthesised and 
provided by Julien Chapelat. The corresponding epoxides were obtained in moderate 
to good yields.   
 
O
O R
R1
R2
O
O R
R1
R2
O
ent-114a
H2O2, MeCN
 
 
entry alkene R1 R2 yieldb (%) dec (%) 
1 143 (-)-Camphd TBS 73 79 
2 144 TIPS TBS 76 73 
3 124 TIPS TIPS 75 82 
4 133 Me (Benzyl)3Sie 84 89 
5 145 Me TIPS 78 85 
6 131 Me Benzyl 87 73 
7 146 (-)-Camphd Anthrf 76 74 
8 125 DPS DPS 81 91 
9 132 Me DPS 81 97 
 
a General experimental conditions: 1 eq. alkene, 0.4 eq. ent-114, 5.4 eq. 
H2O2 (30% aq.) in a buffered (2 M K2CO3 / EDTA) mixture of MeCN: 
EtOH:DCM (1:1:2) at 0 °C, for 10 h. b Isolated yields. c Determined by chiral 
HPLC. d (-)-camphanoyl. e tribenzyl silyl. f 9-methylanthracenyl.     
 
Figure 60: Shi epoxidation of bis-protected hydroquinones.138 
 
Screening of these substrates gave one outstanding result (entry 9) revealing that a 
small R1 group and a large R2 substituent (DPS, tert-butyldiphenylsilylether) are 
required to accomplish high diastereoselectivities in the Shi epoxidation. The 
epoxidation of substrate 132 gave the corresponding epoxide 147 in 81% yield and 
with a de value of 97%. Its HPLC chromatogram is shown in figure 61. It can be 
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assumed that background epoxidation for all examples is below 2% in the absence of 
ketone ent-114.132 
 
 
Figure 61: HPLC chromatogram of the products 147 and 148 of the Shi epoxidation 
of alkene 132 using ketone ent-114. 
 
 
3.2.4 Transformation of Chiral Epoxide 147 to α-Tocopherol (1) via Acid  
         Supported Epoxide Ring Opening 
 
Before the 6-membered chromanol ring formation from epoxide 147 could be 
performed, a suitable method for the removal of the silyl protecting group had to be 
found. Initial studies on the cleavage of the TIPS ether in 149 under usual conditions 
(TBAF, THF) had shown that in this basic reaction medium the undesired 
5-membered ring product 150 is formed exclusively (figure 62).     
 
O
O
Si
149
Si
O
HO
O
OH
150
TBAF, THF
1 h, r.t., 87%
 
Figure 62: Cleavage of the TIPS ether, yielding 5-membered ring product 150.   
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In general, γ-epoxy alcohols preferably cyclise to furans obeying rules published by 
Baldwin in 1976 (figure 63).139 
 
O
OH
OH
O
O
OH
6-endo-tet
disfavoured
5-exo-tet
favoured  
Figure 63: Baldwin rules for γ-epoxy alcohol cyclisations. 
 
A method had to be found to circumvent these rules in order to favour the formation 
of pyrans. In the past two decades, several methods have been published to favour 
the formation of pyrans.140, 141, 142, 143 However, none of the published procedures are 
applicable to the transformation of an epoxide, such as 151, which can be obtained 
from 147, to the chromanol 152 (figure 64).  
 
O
OH
O
O
OH
O
H+
H
O
O
OH
151
152  
Figure 64: Proposed chromanol ring construction. 
 
The following reaction sequence of 147 to α-tocopherol (1) was carried out by Julien 
Chapelat (figure 65).138 Under slightly acidic conditions (AcOH, TBAF, THF) the silyl 
ether in 147 could be cleaved to obtain epoxide 151 without the formation of the 
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corresponding 5-membered ring product (compare figure 62).144 A number of 
different reaction conditions had to be tested in order to obtain cyclisation in favour of 
the pyran product 152. By performing the cyclisation of 151 in a mixture of MeCN and 
2 M HCl in diethylether the desired 6-membered ring product 152 was obtained in 
79% yield and with a de value of 93%. The corresponding 5-membered ring was 
formed as a side product in 19% yield. Finally removal of the hydroxyl group went 
smoothly through the tosylate 153, easily eliminated, and directly hydrogenated to 
afford 154 in almost quantitative yield. Deprotection of the methyl ether could be 
performed without any loss of chirality, by means of BF3·Me2S/AlCl3, giving 
α-tocopherol (1).70 
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O
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Figure 65: Synthesis of α-tocopherol (1) from epoxide 147. 
 
This highly diastereoselective synthesis of α-tocopherol (1) involves a Shi 
epoxidation as the key step. However, the enantiomer ent-114 of the commercially 
available catalyst 114 had to be synthesised in five steps in order to obtain 
α-tocopherol (1) with R-configuration at C(2). It would therefore be desirable to find 
an alternative synthetic pathway for the transformation of alkene 132 to α-tocopherol 
(1) in which the commercially available catalyst 114 could be employed.  
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3.2.5 An Alternative Synthetic Pathway for the Transformation of Alkene 
         132 to α-Tocopherol (1) using Catalyst 114  
 
An alternative strategy for the synthesis of α-tocopherol (1) is shown in figure 66. 
This new route takes into account common knowledge concerning the stereospecific 
ring closure of the tertiary alcohol 155.145 This ring closure occurs under retention of 
configuration, which means that tertiary alcohol 155 has to be obtained with 
R-configuration. This could be done by opening the epoxide in 148 with hydride, 
followed by the removal of the protecting groups. It can be assumed that hydride 
attacks at the less substituted C-atom of the epoxide function, which would yield the 
corresponding alcohol under retention of configuration.50 Epoxide 148 can be 
prepared by asymmetric Shi epoxidation using the commercially available ketone 
catalyst 114.      
 
HO
O R
1
MeO
O R
OHO
OH RHO
Si
155 148
MeO
O R
Si
132
Shi epoxidation
H2CR:
 
Figure 66: Retrosynthetic analysis for the transformation of 148 to 1. 
 
The mechanism of the proton-catalysed ring closure of hydroquinone 155 to α-
tocopherol (1) was reported by Cohen et al. in 1981 (figure 67).145 This conversion 
involves the intermediacy of quinone 156 formed in trace quantity by air oxidation of 
155. The derived hemiketal 157 could then undergo reduction by the starting 
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hydroquinone 155, yielding α-tocopherol (1) and regenerating quinone 156, thus 
establishing a catalytic redox cycle. 
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Figure 67: The mechanism of the proton-catalysed ring closure of 155 to α-
tocopherol (1).145 
 
The alternative synthetic pathway is depicted in figure 68. Olefin 132 (>98:2, E:Z) 
was epoxidised employing the commercially available Shi ketone 114 to give epoxide 
148 (96% de) with R,R-configuration. Epoxide ring opening of 148 could be achieved 
by treatment with LiEt3BH, which yielded the tertiary alcohol 158 in 49% yield. The 
opening of the epoxide function required the refluxing of the reaction mixture for 4 h. 
These relatively harsh reaction conditions led to the formation of side products. 
Attempts to use less reactive LiAlH4 in ether to open the epoxide were unsuccessful. 
Oxidative removal of the protecting groups using CAN afforded quinone 159. 
Subsequent chromanol cyclisation was carried out following a published 
procedure.145  Quinone 159 was first hydrogenated to the corresponding 
hydroquinone 155, subsequent acid catalysed (pTsOH) cyclisation gave α-tocopherol 
(1) in 92% yield and 93% de (figure 69). When the cyclisation was performed in 
MeOH using conc. HCl (aq.) the de value dropped to 82%.146  
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Figure 68: Alternative synthetic pathway for the transformation of olefin 132 to 
α-tocopherol (1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 69: Top: HPLC chromatogram of the products of the cyclisation of 157. 
Bottom: HPLC chromatogram of commercial all racemic α-tocopherol.  
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This alternative synthetic route has several advantages. Firstly, the commercially 
available ketone 114 can be employed for the Shi epoxidation of olefin 132, whereas 
the previously reported route requires the synthesis of ent-114 (5 steps). Secondly, 
this route is considerably shorter in terms of number of reaction steps (8 vs. 10) as 
well as overall reaction time. 
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4 Summary and Conclusions 
 
Vitamin E exists in eight different forms, four tocopherols and four tocotrienols. All 
possess a hydrophobic side chain, which allows them to penetrate into biological 
membranes. Their second common feature is a chromanol moiety with a hydroxyl 
group that can donate a hydrogen atom. These properties make vitamin E a very 
important radical chain-breaking antioxidant in living organisms, and therefore also 
an industrial product.  
 
α-Tocopherol is the member of the vitamin E family that is preferentially absorbed 
and accumulated in humans. There are three stereocenters in α-tocopherol, whereas 
RRR-α-tocopherol (1) is the natural and biologically most active form. The 
R-configuration at C(2) is essential in order to be recognised by the α-tocopherol 
transport protein and thus maintained in the plasma. The biological activity rendered 
RRR-α-tocopherol (1) a synthetic target. 
 
In this work two novel syntheses of RRR-α-tocopherol (1) are presented. Both 
syntheses involve a highly diastereoselective epoxidation of the bis-protected phytyl 
hydroquinone 132 as the key step followed by a cyclisation to form the chromanol 
ring (figure 70). 
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O
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H2CR:  
Figure 70: Asymmetric epoxidation of 132 giving 147 or 148. 
  
In order to find suitable stereoselective epoxidation catalysts, cyclodextrin-based 
catalysts were prepared and tested (figure 71). However, none of these catalysts 
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were reactive or selective enough to be applicable to the epoxidation of bis-protected 
phytyl hydroquinones. 
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Figure 71: Cyclodextrin based catalysts 
 
However, the asymmetric Shi epoxidation proved to be a suitable epoxidation 
method for this purpose. A number of bis-protected phytyl hydroquinones were 
synthesised and subsequently epoxidised under Shi epoxidation conditions. The 
highest diastereoslectivity could be obtained for substrate 132. By applying Shi 
ketone 114, which is derived from D-fructose, epoxide 148 could be obtained with 
96% de, whereas if the enantiomer ent-114 (synthesised in 5 steps from L-sorbose) 
was used, 147 was formed with 97% de (figure 71). 
 
O
O
O
O
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O
O
O
O
O
O
ent-114  
Figure 71: D-fructose derived Shi ketone 114 and its enantiomer ent-114. 
 
The epoxide function in 148 could be selectively opened with hydride. Further 
transformations led to the hydroquinone 155, which could be cyclised under acidic 
conditions to form the chromanol ring of 1 with the desired R-configuration at C(2) 
(figure 72). α-Tocopherol could be synthesised in 8 steps with 93% de via this route. 
To the best of my knowledge, this highly diasteroselective synthesis of α-tocopherol 
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(1) is one of the shortest in terms of numbers of steps, employing a commercially 
available organocatalyst.  
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Figure 72: Transformation of epoxide 148 to α-tocopherol (1). 
 
In a different approach an acid supported, “anti-Baldwin” epoxide ring opening of 
desilylated 147 under inversion of configuration led to the 6-membered chromanol 
ring. α-Tocopherol could be synthesised in 10 steps and with 93% de. This synthesis 
was carried out in collaboration with Julien Chapelat. 
 
To the best of our knowledge this is the second application of an organocatalyst to 
the construction of chromanols, having a tetrasubstituted chiral carbon centre, in high 
diastereoselectivity.70   
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5 Experimental Part 
 
5.1 General Remarks  
 
5.1.1  Solvents and Reagents 
 
Reagents were used as received from Fluka AG, Acros Organics and Aldrich unless 
otherwise stated. Chemicals of the quality purum, purum p.a. or > 98% were used 
without further purification. 6-O-monotosyl-β-CD (85) was purchased from 
CycloLab Ltd (Budapest, Hungary). 
Solvents for chromatography and extractions were distilled prior to use. Solvents 
used for reactions corresponded to the quality puriss p.a., abs., over molecular 
sieves from Fluka AG. HPLC-grade solvents were purchased and used for analytical 
HPLC on chiral phase (Chiralcel OD-H and Chiralcel AD-H).  
For an inert atmosphere Argon 56 (< 4 ppm other gases) from Carbagas AG 
(Lenzburg, Switzerland) or Argon 6.0 (<1.5 ppm other gases) from PanGas AG 
(Dagmersellen, Switzerland) were used. 
 
 
5.1.2 Materials and Instruments 
 
Solvents were removed with a Büchi (Switzerland) rotary evaporator (Waterbath 461, 
Rotavapor RE 111 and Vauum Controller 168) and a MZ 2C membrane pump 
(Vacuubrand). For cooling a mixture of EtOH and water was kept at 2 °C with a UKW 
300 thermostat (Vacuubrand). 
For weighing compounds and reagents Mettler (Switzerland) balances P1200 (>1g), 
AE 163 (<1g), and AX205 (<100mg) were used. 
A high-vacuum pump D5E from Trivac (Köln, Germany) was used for drying 
compounds.  
For all non-aqueous reactions glassware was dried with a heat gun for several 
minutes under vacuum, and the atmosphere was exchanged by three cycles of 
evacuating and flushing with argon. 
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Melting points (mp) were determined on a büchi 510 apparatus and are 
uncorrected. 
 
Elemental Analysis (EA) was performed with a Perkin-Elmer 240 Analyser by Mr. 
W. Kirsch at the Department of Chemistry, University of Basel. Description: EA 
(chemical formula, molecular weight): calculated (calc.) abundance of C, H in %; 
found abundance of C, H in %. 
 
 
Chromatographic Methods 
 
Analytical thin layer chromatography (TLC) was performed on 0.25 mm precoated 
glass plates (5×10 cm, silica gel 60 F254, Merck AG, Germany), 0.25 mm precoated 
glass plates (5×10 cm, aluminium oxide 60 F254, Merck AG, Germany), or on 
0.25 mm precoated glass plates (5×10 cm, RP-18 F254s, Merck AG, Germany). 
Compounds were detected at 254 nm (UV) or at 366 nm (fluorescence). For 
carbohydrates, compounds were visualized by p-anisaldehyde dip (6 g             
p-anisaldehyde and 3 ml concentrated sulphuric acid in 250 ml ethanol). Description: 
(solvent): Rf.  
For normal phase column chromatography silica gel 60 from Merck (0.040-0.063 
mm, 230-400 mesh) or aluminum oxide 90 from Merck (standardized (activity II-III), 
0.063-0.2 mm, 70-230 mesh) were used. For reversed phase column 
chromatography, RP-18 silica gel (fully endcapped) from Fluka (0.040-0.063mm, 
230-400 mesh) was used. Flash chromatography was performed under pressure with 
an aquarium pump. 
Analytical chiral phase HPLC (ee determination) was performed with a Chiralcel 
OD-H or a Chiralcel AD-H column using HPLC-grade solvents on a Agilent 1100 
Series HPLC system with Solvent degasser G1322A, BinPump G1312A, 
Autosampler G1313A, Thermostatic column housing G1316A, Diode array UV 
detector G1315B. All samples were filtrated prior to injection.  
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Spectroscopic Methods 
 
Infrared spectras (IR) were measured on a Perkin-Elmer 1600 series FTIR 
spectrometer in KBr or on a FTIR-8400S from SHIMADZU. Description: IR (medium): 
wavenumbers of transmission maxima in cm-1. 
 
Electron spray ionization mass spectra (ESI-MS) were recorded on a Bruker 
Esquire 3000plus. Description: ESI-MS (solvent): mass peaks in m/z. 
 
Electron impact mass spectra (EI-MS) were measured by Dr. H. Nadig on a Varian 
double focussing VG-70-250 spectrometer at the Department of Chemistry, 
University of Basel. Description: MS(EI): mass peaks in m/z (relative intensity in %). 
 
1H-Nuclear magnetic resonance spectroscopy (1H-NMR) was performed using 
either a Bruker av250 (250MHz), Bruker DPX-NMR (400MHz), Bruker DRX-500 
(500MHz) or Bruker DRX-600 (600MHz) spectrometer. Solvents for NMR were 
obtained from Cambridge Isotope Laboratories (Andover, MA, USA). CDCl3 was 
filtered through basic alumina prior to use. All spectra were recorded at 298 K. 
Description: 1H-NMR (frequency, solvent): δH in ppm relative to TMS or residual 
solvent peaks (CDCl3: 7.26, D2O: 4.79). Peak multiplicity: s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet; coupling constants J in Hertz. 
 
13C-Nuclear magnetic resonance spectroscopy (13C-NMR) was 1H-decoupled and 
recorded on a Bruker DPX-NMR (100MHz) or Bruker DRX-500 (125 MHz) 
spectrometer. For the assignment of carbons ATP, DEPT, HETCOR, HMQC and 
HMBC experiments were carried out. Description: 13C-NMR (frequency, solvent):     
δC in ppm relative to residual solvent peaks. 
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5.2 Syntheses 
 
5.2.1  Syntheses of Cyclodextrin Catalysts and Catalytic Reactions 
 
2,6-bis(bromomethyl)pyridine (87) 
 
A solution of 4.00 g diol (86) (28.7 mmol, 1.0 eq.) in 60 mL 48% 
HBr was heated to reflux for 17 h. After being cooled to 0 °C, 
the reaction mixture was neutralised with 40% NaOH. The 
mixture was extracted with DCM (3x) and the combined organic phases were dried 
over Na2SO4. Chromatography (SiO2, DCM) yielded 4.02 g (15.2 mmol, 53%) of a 
white solid. 
 
TLC (SiO2, DCM): Rf = 0.41. 
1H-NMR (400 MHz, CDCl3): 4.55 (s, 4H, CH2), 7.39 (d, J = 7.8 Hz, 2H, Har), 7.73 (t, J 
= 7.8 Hz, 1H, Har). 
13C-NMR (100 MHz, CDCl3): 33.3, 123.1, 138.5, 156.8. 
MS (EI): m/z (%) = 266.9 (8), 264.9 (17), 262.9 ([M+], 9), 186.0 (97), 184.0 (100).  
EA: calculated for C7H7N1Br2: C 31.73, H 2.66, N 5.29; found: C 31.68, H 2.55, 
N 5.32. 
 
2-((6-(bromomethyl)pyridin-2-yl)methyl)isoindoline-1,3-dione (88) 
 
A suspension of 3.75 g dibromide (87) (14.2 mmol, 1.0 
eq.), 5.89 g K2CO3 (42.6 mmol, 3.0 eq.), 2.88 g 
phthalimide potassium salt (15.6 mmol, 1.1 eq.) and 
150 mL abs. MeCN was refluxed for 3 h. The solvent 
was removed in vacuo and the residue was dissolved in a DCM/H2O mixture. The 
phases were separated and the aqueous phase was extracted with DCM (2x). The 
combined organic phases were dried over Na2SO4. Chromatography (SiO2, 
hexane/EtOAc = 6:4) yielded 2.07 g (6.25 mmol, 44%) of a white solid. 
 
TLC (SiO2, hexane/EtOAc = 1:1): Rf = 0.41. 
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1H-NMR (400 MHz, CDCl3):  4.51 (s, 2H, Br-CH2), 5.05 (s, 2H, N-CH2), 7.16 (d, J = 
7.8 Hz, 1H, Br-CH2CCH), 7.37 (d, J = 7.7 Hz, 1H, N-CH2CCH), 7.67 (t, J = 7.8 Hz, 
1H, NCCHCH), 7.75 (dd, J = 3.0, 5.4 Hz, 2H, CH phthalimide), 7.90 (dd, J = 3.0, 5.4 
Hz, 2H, CH phthalimide). 
13C-NMR (100 MHz, CDCl3): 33.2, 42.7, 120.7, 122.7, 123.7, 132.3, 134.3, 138.4, 
155.2, 156.7, 168.2. 
ESI-MS (MeOH): Positive ion mode: 331.0 ([M+H]+), 333.0, 352.9 ([M+Na]+), 354.9. 
EA: calculated for C15H11N2O2Br: C 54.40, H 3.35, N 8.46; found: C 54.36, H 3.23, 
N 8.49. 
 
2-((6-((bis(pyridin-2-ylmethyl)amino)methyl)pyridin-2-yl)methyl)isoindoline-1,3-
dione (89) 
To a suspension of 1.23 mL di-(2-picolyl)amine 
(6.84 mmol, 1.1 eq.) and 1.29 g K2CO3 (9.33 
mmol, 1.5 eq.) in 50 mL abs. MeCN was added 
a solution of 2.06 g bromide (88) (6.22 mmol, 
1.0 eq.)  in 20 mL abs. DMF over a period of 10 
min at 88 °C. The reaction mixture was refluxed 
for 3 h and the solvent was then removed in vacuo. Chromatography (Al2O3, EtOAc) 
yielded 2.30 g (5.11 mmol, 82%) of a white solid. 
 
TLC (Al2O3, EtOAc): Rf = 0.45. 
1H-NMR (400 MHz, CDCl3): 4.22 (br s, 6H, N(CH2)3), 5.00 (s, 2H, N-CH2), 7.15-7.22 
(m, 3H, Har), 7.44 (d, J = 7.7 Hz, 1H, Har), 7.58-7.76 (m, 7H, Har), 7.87 (dd, J = 3.0, 
5.5 Hz, 2H, Har), 8.49 (d, J = 5.0 Hz, 2H, Har). 
13C-NMR (100 MHz, CDCl3): 43.3, 60.2, 60.6, 119.7, 122.1, 122.3, 123.4, 123.8, 
132.6, 134.4, 136.8, 137.5, 149.4, 155.0, 159.7, 159.8, 168.6. 
ESI-MS (MeOH):  Positive ion mode: 472.1 ([M+Na]+);  
  Negative ion mode: 448.2 ([M-]). 
EA: calculated for C27H23N5O2: C 72.14, H 5.16, N 15.58; found: C 71.29, H 5.18, 
N 15.29. 
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(6-(aminomethyl)pyridin-2-yl)-N,N-bis(pyridin-2-ylmethyl)methanamine (90) 
 
To a solution of 2.25 g of phthalimide (89) (5.01 mmol, 
1.0 eq.) in 110 mL MeOH was added 0.56 mL 
hydrazine monohydrate (11.5 mmol, 2.3 eq.). The 
reaction mixture was refluxed for 7 h and the solvent 
was removed in vacuo. The residue was then 
dissolved in CHCl3 and washed with 1 M NaOH and 
brine. The organic phase was dried over Na2SO4. Chromatography (Al2O3, 
DCM/MeOH = 20:1 to 5:1) yielded 1.40 g (4.38 mmol, 87%) of a light yellow oil. 
 
TLC (Al2O3, DCM/MeOH = 20:1): Rf = 0.23. 
1H-NMR (400 MHz, CDCl3): 2.00 (br s, 2H, NH2), 3.87 (s, 2H, N-CH2), 3.88 (s, 4H, N-
CH2), 3.94 (s, 2H, NH2-CH2), 7.10-7.15 (m, 3H, Har), 7.42 (d, J = 7.7 Hz, 1H, Har), 
7.57-7.67 (m, 5H, Har), 8.52 (d, J = 4.9 Hz, 2H, N-CH). 
13C-NMR (100 MHz, CDCl3): 48.1, 60.5, 60.6, 119.8, 121.3, 122.4, 123.3, 136.8, 
137.4, 149.5, 159.3, 159.9, 161.5. 
ESI-MS (MeOH):  Positive ion mode: 320.1 ([M+H]+), 324.1 ([M+Na]+). 
 
mono-6-deoxy-6-(N-6-methylpyridin-2-yl)-N,N-bis(pyridin-2-ylmethyl)-
methanamine (91) 
 
A mixture of 1.40 g amine (4.38 mmol, 25 
eq.) and 229 mg monotosylated 
cyclodextrin (85) was heated to 70 °C for 
3 h. Then 0.4 mL abs. DMF was added and 
the reaction mixture was stirred at 70 °C for 
17 h. The mixture was added dropwise to 
150 mL acetone, the precipitate was filtered off and washed with acetone. The 
precipitate was then redissolved in 0.4 mL DMF and added again to 150 mL acetone, 
filtered off and washed again with acetone. This procedure was repeated once more. 
One obtained 227 mg (0.158 mmol, 89%) of a white solid. 
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1H-NMR (500 MHz, MeOH-d4): 2.80-4.50 (m, 50H,7xH2/3/4/5/6 and 4xCH 4.90-5.04 
(m, 6H, 6xH1), 5.12 (d, J = 3.4 Hz, 1H, 1xH1), 7.11 (d, J = 7.8 Hz, 1H, N-CCH), 7.30-
7.33 (m, 3H, N-CCH and NCHCH), 7.57 (d, J = 8.2 Hz, 2H, N-CHCHCHCH), 7.60 (t, 
J = 7.8 Hz, 1H, N-CCHCH), 7.84 (m, 2H, N-CHCHCH), 8.49 (d, J = 4.4 Hz, 2H, N-
CH). 
ESI-MS (MeOH):  Positive ion mode: 1436.1 ([M+H]+), 1458.0 ([M+Na]+). 
 
Catalytic epoxidation of 1-allyl-4-tert-butylbenzene (92) using catalyst 91 to 
give 2-(4-tert-butylbenzyl)oxirane (93) 
 
A solution of 14.8 mg of 91 (10.3 μmol, 0.06 eq.) and 2.0 mg 
of MnCl2·4H2O (10.3 μmol, 0.06 eq.) in 6 mL H2O/MeCN (1:1) 
was stirred for 1 h at r.t. before a solution of 30 mg 1-allyl-4-
tert-butylbenzene (92) (172 μmol, 1.0 eq.) in 3 mL MeCN was added. To the resulting 
solution a solution of 189 mg iodosylbenzene (861 μmol, 5.0 eq.) was added over a 
period of 20 min. The reaction mixture was stirred for 2 h at r.t.. The reaction was 
quenched by the addition of Na2S2O3 and H2O. The mixture was extracted with 
hexane (3x). The combined organic phases were dried over Na2SO4 and the crude 
product was purified by column chromatography (SiO2, hexane/EtOAc = 10:1) to give 
15.7 mg (82.6 μmol, 48%) of a colourless oil.  
 
TLC (SiO2, hexane/EtOAc = 10:1): Rf = 0.32. 
1H-NMR (250 MHz, CDCl3): 1.35 (s, 9H, CH3), 2.59 (dd, J = 2.7 Hz, 5.0 Hz, 1H, 
OCH2), 2.75-2.86 (m, 2H, OCH2 + CCH2), 2.95 (dd, J = 5.5 Hz, 14.5 Hz, 1H, CCH2), 
3.18 (m, 1H, OCH), 7.22 (d, J = 8.2 Hz, 2H, Har), 7.37 (d, J = 8.2 Hz, 2H, Har). 
13C-NMR (100 MHz, CDCl3): 31.7, 34.8, 38.7, 47.4, 52.9, 125.9, 129.1, 134.5, 149.9. 
 
Catalytic Oxidation of 1-tert-Butyl-4-propylbenzene (94) Using Catalyst 91  
 
A solution of 9.0 mg of 94 (51 μmol, 1.0 eq.), 7.3 mg of 91 (5.1 μmol, 0.1 eq.) and 
1.0 mg of MnCl2·4H2O (5.1 μmol, 0.1 eq.) in 3 mL MeCN/H2O (2:1) was stirred at r.t. 
for 30 min. Then 140 μL TBHP (70% in H2O) (1.0 mmol, 20 eq.) was added and the 
resulting mixture was stirred for 5 h at r.t. The mixture was then  analysed by gas 
O
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chromatography using a Finnigan Focus GC-FID with a 15 m Supelcowax column, 
after being extracted with hexane.   
GC: tret = 2.22 min (30%) 94,  6.68 min (68%) ketone 95, 7.61 min (2%) alcohol 96. 
 
Catalytic Oxidation of tert-Butyl-cyclohexane (97) Using Catalyst 91 
 
A solution of 3.0 mg of 91 (2.1 μmol, 0.1 eq.), 0.41 mg of MnCl2·4H2O (5.1 μmol, 
0.1 eq.) and 2.9 mg tert-butyl-cyclohexane (97) (21 μmol, 1.0 eq.) was stirred at r.t. 
for 30 min. Then 143 μL TBHP (70% in H2O) (1.0 mmol, 500 eq.) were added and 
the resulting solution was stirred at r.t. for 17 h. The mixture was then  analysed by 
gas chromatography using a Finnigan Focus GC-FID with a 15 m Supelcowax 
column, after being extracted with hexane.   
GC: tret = 5.98 min (37%), 6.07 (14%), 6.07, 6.34, 6.54. 
 
(3R,4R)-N-benzyl-3,4-dihydroxy-2,5-dioxopyrrolidine (102)116 
 
To a suspension of 45.0 g (300 mmol, 1.0 eq.) L-(R,R)-(+)-tartaric 
acid (101) in 200 mL of o-xylene was added 32.1 g (300 mmol, 1.0 
eq.) of benzylamine and the mixture was refluxed with stirring in a 
round-bottomed flask equipped with a Dean-Stark apparatus. The 
reaction was complete when the appropriate amount of water was 
collected (10.8 mL, 600 mmol, 4 h). After cooling the reaction mixture to r.t., the 
product was filtered off and recrystallised from ethanol to give 34.0 g (153 mmol, 
51%) of a white solid. 
 
1H-NMR (400 MHz, (CD3)2SO): 4.36 (d, J = 6.6 Hz, 2H, NCH2Car), 4.53 (m, 2H, 
HOCHCO), 6.27 (d, J = 7.1 Hz, 2H, OH), 7.23 (m, 3H, Har), 7.31 (m, 2H, Har). 
13C-NMR (100 MHz, CDCl3): 42.0, 75.3, 128.3, 128.4, 129.4, 136.8, 175.4. 
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(3S,4S)-N-benzyl-3,4-dihydroxypyrrolidine (103)116 
 
5.13 g (135 mmol, 2.3 eq.) Lithium aluminium hydride was slowly 
added to a 0 °C cooled solution of 13.0 g (58.8 mmol, 1.0 eq.) of 102 
in 235 mL abs. diethyl ether. The reaction mixture was refluxed for 
48 h. At 0 °C, 15 mL EtOAc were slowly added, followed sequentially 
by 5.1 mL water, 5.1 mL 15% NaOH and 15.3 mL water. The resulting 
mixture was stirred for 1 h, filtered over celite and dried over Na2SO4. After 
evaporation of the solvent under reduced pressure, the resulting oil was crystallised. 
The crude product was recrystallised form EtOAc to give 5.34 g (27.6 mmol, 47%) of 
a white solid.    
 
TLC (SiO2, DCM/MeOH + 1% Et3N = 10:1): Rf =0.21. 
1H-NMR (400 MHz, CDCl3): 2.41 (dd, J = 4.3 Hz, 10.3 Hz, 2H, NCH2CH), 2.88 (dd, 
J = 5.8 Hz, 10.1 Hz, 2H, NCH2CH), 3.52 (d, J = 12.6 Hz, 1H, HOCHCH2), 3.61 (d, J = 
12.6 Hz, 1H, HOCHCH2), 4.03 (m, 2H, NCH2Car), 4.41 (br s, 2H, OH), 7.27 (m, 5H, 
Har).  
13C-NMR (100 MHz, CDCl3): 60.2, 60.4, 78.2, 127.7, 128.5, 129.4, 137.1. 
 
(3S,4S)-1-benzylpyrrolidine-3,4-diyl dimethanesulfonate (104)117 
 
To a 0 °C cooled solution of 2.50 g (12.9 mmol, 1.0 eq.) of 103 and 
3.6 mL (25.9 mmol, 2.0 eq.) Et3N in 20 mL abs. DCM, was added 
2.00 mL (25.9 mmol, 2.0 eq.) methanesulfonyl chloride over a period 
of 15 min. The mixture was stirred for 30 min at r.t. and subsequently 
washed with water (2x). The DCM phase was then extracted with 
1 M HCl. The aqueous phase was made basic with 20% NaOH and 
extracted with DCM (2x). The combined organic phases were washed with brine and 
dried over Na2SO4. One obtained 4.45 g (12.7 mmol, 99%) of a colourless oil. 
 
TLC (SiO2, hexane/EtOAc = 1:1): Rf =0.21. 
1H-NMR (400 MHz, CDCl3): 2.81 (m, 2H, NCH2CH), 3.09 (s, 6H, CH3), 3.14 (m, 2H, 
NCH2CH), 3.68 (m, 2H, NCH2Car), 5.15 (m, 2H, OCH), 7.27-7.36 (m, 5H, Har). 
13C-NMR (100 MHz, CDCl3): 38.8, 58.1, 59.7, 82.5,128.3, 129.0, 129.3, 137.5. 
N
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(3R,4R)-(-)-3,4-Diazido-1-(phenylmethyl)pyrrolidine (105)147 
 
A stirred mixture of 2.50 g (12.9 mmol, 1.0 eq.) of 104 and 2.40 g 
(36.9 mmol, 3.0 eq.) of NaN3 in 19 mL dry DMF was heated to 100 °C 
for 4 h. The solvent was removed in vacuo. The residue was dissolved 
in DCM and washed with saturated NaHCO3 and brine and was dried 
over Na2SO4. Chromatography (SiO2, hexane/EtOAc = 5:1) afforded 
2.08 g (8.57 mmol, 70%) of a colourless oil. 
 
TLC (SiO2, hexane/EtOAc = 2:1): Rf =0.66. 
1H-NMR (400 MHz, CDCl3): 2.60 (dd, J = 4.8 Hz, 9.8 Hz, 2H, NCH2CH), 2.99 (dd, J = 
4.8 Hz, 9.8 Hz, 2H, NCH2CH), 3.62 (d, J = 13.0 Hz, 2H, NCH2Car), 3.67 (d, J = 
13.0 Hz, 2H, NCH2Car), 3.87 (m, 2H, NCH), 7.29-7.35 (m, 5H, Har). 
13C-NMR (100 MHz, CDCl3): 58.1, 59.8, 66.2, 127.4, 127.8, 128.9, 129.0,129.1, 
138.1. 
 
6,6'-(1E,1'E)-(3R,4R)-pyrrolidine-3,4-diylbis(azan-1-yl-1-ylidene)bis(methan-1-yl-
1-ylidene)bis(2,4-di-tert-butylphenol) (99)118 
 
197 mg Palladium on carbon (10% w/w) 
was added to a solution of 536 mg (2.20 
mmol, 1.0 eq.) of 105 in a mixture of 5.7 mL 
EtOH and 1.43 mL TFA. The suspension 
was stirred under 1 atm hydrogen for 46 h, 
filtered through Celite, and concentrated 
under vacuum. The crude residue was 
dissolved in 18 mL EtOH/H2O (9:1) and neutralized with 1.06 g (7.70 mmol, 3.5 eq.) 
potassium carbonate. 1.13 g (4.84 mmol, 2.2 eq.) of neat 3,5-di-tert-butyl-
salicylaldehyde (106) was added at once and the reaction was heated to reflux for 
2 h. The reaction mixture was then poured into 40 mL brine and extracted with DCM 
(3x). The organic phases were combined and washed with brine, dried over Na2SO4, 
and concentrated. The crude product was purified by chromatography (SiO2, 
TBME:hexane = 2:1) to give 818 mg (1.53 mmol, 70%) of a foamy yellow solid. 
 
N
N3 N3
N N
HOOH
H
N
Experimental Part 
 - 86 -     
TLC (SiO2, hexane/TBME = 1:2): Rf =0.11. 
1H-NMR (400 MHz, CDCl3): 1.27 (s, 18 H, C(CH3)3), 1.45 (s, 18 H, C(CH3)3), 3.17 
(dd, J = 11.9 Hz, 4.8 Hz, 2H, NHCH2CH), 3.50 (dd, J = 11.9 Hz, 4.8 Hz, 2H, 
NHCH2CH), 3.89 (m, 2H, NHCH2CH), 7.05 (d, J = 2.0, 2H, Har), 7.38 (d, J = 2.0, 2H, 
Har), 8.34 (s, 2H, NCHC), 13.37 (s, 2H, OH). 
13C-NMR (100 MHz, CDCl3): 29.6, 31.6, 34.3, 35.2, 54.9, 117.7, 126.4, 127.4, 136.8, 
140.5, 157.9, 166.5. 
 
CD-Modified Salen Ligand 100 
 
A mixture of 50 mg 99 (94 μmol, 1.0 eq.), 
241 mg 85 (187 μmol, 2.0 eq.) and 48 μL 
Hünig’s base (281 μmol, 3.0 eq.) and 0.4 mL 
dry DMF was stirred at 100 °C for 24 h. The 
solvent was removed under reduced pressure. 
The crude product was purified by column 
chromatography (RP-18, MeOH/H2O = 2:1 to 
MeOH) to give 76 mg (46 μmol, 49%) of a 
yellow solid. 
 
 
TLC (RP-18, MeOH): Rf =0.11. 
ESI-MS (MeOH): Positive ion mode: 1673.4 ([M+Na]+). 
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CD-Modified Mn Salen Complex 107 
 
A suspension of 30 mg of 100 (18 μmol, 
1.0 eq.) in 0.5 mL EtOH was heated to reflux. 
13 mg Mn(OAc)4·4H2O (55 μmol, 3.0 eq.) was 
added and the mixture was refluxed for 2 h. 
Then 2.3 mg LiCl (55 μmol, 3.0 eq.) was 
added and the mixture was refluxed for 
another hour under air. The mixture was 
allowed to cool to r.t. and the solvent was 
removed under reduced pressure. The crude 
product was purified by column 
chromatography (RP-18, MeOH/H2O = 1:1 to 
MeOH) to give 26 mg (15 μmol, 82%) of a brown solid. 
 
ESI-MS (MeOH): Positive ion mode: 1703.1 ([M+Na]+). 
 
Catalaytic Epoxidation of 4-tert-Butylstyrene (108) Using Catalyst 107 
 
To a suspension of 7.3 mg of 108 (45 μmol, 1.0 eq.) and 3.9 mg of 107 (2.3 μmol, 
0.05 eq.) in 0.3 mL DCM was added 27.0 mg of NMO (227 μmol, 5.0 eq.). To the 
resulting solution was added 23.5 mg of mCPBA (136 μmol, 3.0 eq.) and the reaction 
mixture was stirred at r.t. for 2 h. DCM was added and the mixture was washed with 
saturated NaOH and brine. The organic phase was dried over Na2SO4. The crude 
product was filtered over silica gel (hexane/EtOAc = 20:3) and analysed by gas 
chromatography using a Finnigan Focus GC-FID with a 15 m Supelcowax column. 
 
GC: tret = 2.43 min (38%) 108, 4.45 min (62%) epoxide 109. 
HPLC (Chiralcel OD-H, n-heptane, 0.5 mL/min, 220 nm): t = 21.14 min (54.5%) 109, 
t = 22.75 min (45.5%) 109.  
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CD-Modified (1S)-(+)-10-Camphorsulfonyl (113)  
 
To a mixture of 1.00 g β-CD (881 μmol, 3.0 eq.), 0.9 
mL abs. Pyridine and 5.5 mL abs. DMF was added at 
0 °C 74 mg of (1S)-(+)-10-camphorsulfonyl chloride 
(294 μmol, 1.0 eq.). The reaction mixture was stirred 
for 4 h at r.t. and then added dropwise to 150 mL 
acetone. The precipitate was filtered off and purified by colummn chromatography 
(RP-18, gradient H2O to MeOH) to give 222 mg (165 μmol, 56%) of a white solid. 
 
TLC (SiO2, EtOAc/isopropanol/NH3 (30%)/H2O = 7:7:5:4): 0.34. 
ESI-MS (MeOH): Positive ion mode: 1371.7 ([M+Na]+). 
1H-NMR (400 MHz, DMSO): 0.79 (s, 3H, CH3), 0.99 (s, 3H, CH3), 1.40 (m,1H), 1.54 
(m, 1H), 1.90 (m, 2H), 2.04 (m, 1H), 2.22 (m, 2H), 3.20-3.75 (m, overlapped with 
water), 3.92 (m, 1H), 4.47 (m, 7H), 4.85 (m, 6H), 5.78 (m, 13H). 
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5.2.2 Synthesis of L-fructose-derived Shi-ketone catalyst ent-114 
Mesylate 138 
 
A solution of 10 mL dry 1,2-dimethoxyethane containing 250 mg 
SnCl2 (1.32 mmol) was added to a suspension of 50.0 g L-
sorbose (pulverized) (278 mmol, 1.0 eq.) in 150 mL 2,2-
dimethoxypropane with vigorous stirring. The mixture was 
refluxed gently with stirring under argon at 70 °C for 2.3 h. At 
this point, there is still a substantial amount of solid (L-sorbose) remaining in the 
reaction mixture. The reaction was quenched immediately with 1.25 mL Et3N, filtered 
to remove the unreacted L-sorbose, and the solid was washed with 15 mL EtOAc. 
The filtrate was concentrated to give a syrup. 
The syrup was dissolved in 121 mL pyridine. After cooling with an ice bath, 26.6 mL 
methanesulfonyl chloride (343 mmol, 1.2 eq.) was added dropwise over 2 h. After 
stirring at 0 °C for an additional 3 h, the reaction mixture was poured into 750 mL ice-
water, stirred for 30 min, and filtered. The filter cake was washed with water several 
times and recrystallized from ethanol (ca. 85 mL) to give 34.9 g mesylate (103 mmol, 
37% yield over two steps based on L-sorbose) as a white crystal. 
 
TLC (SiO2, EtOAc): Rf = 0.32. 
mp: 121 – 122 °C. 
[α]D20 = -28.1 (c = 1.06 in CHCl3). 
1H-NMR (500 MHz, CDCl3): 1.35 (s, 3H, C-CH3), 1.39 (s, 3H, C-CH3), 1.44 (s, 3H, C-
CH3), 1.51 (s, 3H, C-CH3), 3.13 (s, 3H, S-CH3), 3.89 (dd, J = 13.0, 3.0 Hz, 1H, O-CH-
CH2), 3.98 (dd, J = 13.0, 3.1 Hz, 1H, O-CH-CH2), 4.18 (d, J = 9.8 Hz, 1H, C-CH2-O), 
4.20 (m, 1H, CH-CH-CH), 4.22 (d, J = 9.8 Hz, 1H, C-CH2-O), 4.43 (m, 1H, O-CH-
CH2), 4.85 (d, J = 1.7 Hz, 1H, S-CH). 
13C-NMR (125 MHz, CDCl3): 20.0, 25.8, 26.0, 28.2, 38.9, 60.4, 72.2, 73.3, 73.4, 84.3, 
98.3, 109.9, 111.6. 
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Alcohol 142 
 
A suspension of 33.7 g mesylate 138 (pulverised) (99.6 mmol, 1.0 
eq.) in 337 mL 4.5% (w) H2SO4 was stirred at r.t. until all the 
starting material had been consumed as monitored by TLC (3 h). 
After it was made alkaline with 67 mL 9 M NaOH (600 mmol), the 
reaction mixture was heated at 90 – 100 °C until the reaction was 
completed as monitored by TLC (8 h). After being acidified to pH ~ 1 with 9 M H2SO4 
(~17 mL), the reaction mixture was heated at 70 – 80 °C for 30 min, neutralized (pH 
7.0) with 9 M NaOH (~15 mL), and concentrated to give a residue. The resulting 
residue was extracted by refluxing with ethanol (4 x 170 mL). The ethanol solution 
was concentrated to give L-fructose as a yellow syrup. 
To a suspension of the above L-fructose syrup in 169 mL acetone was added 
36.7 mL 2,2-dimethoxypropane (300 mmol, 3.0 eq.). After cooling to 0 °C, 1.4 mL 
concentrated H2SO4 (25 mmol) was added dropwise under argon. The resulting 
reaction mixture was stirred at 0 °C for 6 h. After addition of 8.5 mL concentrated 
NH4OH, the reaction mixture was concentrated to a solid which was then dissolved in 
135 mL DCM. The resulting solution was washed H2O (2 x 70 mL), brine (70 mL), 
dried over Na2SO4, filtered, concentrated, and purified by silica gel chromatography 
(EtOAc/hexane = 1:5 to 1:3) to give 9.89 g (38.0 mmol, 38%) of a white solid.  
  
TLC (SiO2, hexane/EtOAc = 2:1): Rf = 0.17. 
mp: 114-116 °C. 
[α]D20 = +143.0 (c = 1.05 in CHCl3). 
1H-NMR (250 MHz, CDCl3): 1.36 (s, 3H, CH3), 1.43 (s, 3H, CH3), 1.50 (s, 3H, CH3), 
1.52 (s, 3H, CH3), 2.08 (d, J = 8.3 Hz, 1H), 3.65 (dd, J = 8.2, 6.9 Hz, 1H), 3.99 (d, J = 
9.0 Hz, 1H), 4.02 (d, J = 13.2 Hz, 1H), 4.13 (dd, J = 13.2, 2.7 Hz, 1H), 4.14 (dd, J = 
6.9, 5.7 Hz, 1H), 4.19 (d, J = 9.0 Hz, 1H), 4.21 (ddd, J = 5.7, 2.7, 0.6 Hz, 1H). 
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Ketone ent-114 
 
To a solution of 1.00 g alcohol 142 (3.84 mmol, 1.0 eq.) in 10 mL 
DCM was added 2.26 g PDC (6.01 mmol, 1.6 eq.), followed by 
3.8 g freshly powdered 3 Å molecular sieves and 1 drop of acetic 
acid. After stirring at r.t. under argon overnight, the reaction mixture 
was filtered through a pad of silica gel and washed (EtOAc/hexane 
= 1:1, 50 mL) until no product came out. The filtrate was concentrated and 
recrystallized from hot hexane (ca. 4.5 mL) to give 810 mg (3.14 mmol, 82%) white 
crystals. 
 
TLC (SiO2, hexane/EtOAc = 2:1): Rf = 0.38. 
mp: 98 – 100 °C. 
[α]D20 = +120.2 (c = 1.00 in CHCl3). 
1H-NMR (500 MHz, CDCl3): 1.39 (s, 6H, CH3), 1.45 (s, 3H, CH3), 1.54 (s, 3H, CH3), 
3.99 (d, J = 9.5 Hz, 1H, C-CH2-O), 4.11 (d, J = 13.5 Hz, 1H, CH-CH2-O), 4.38 (dd, J = 
13.5, 2.1 Hz, 1H, CH-CH2-O), 4.54 (dd, J = 5.5, 2.1 Hz, 1H, CH-CH2-O), 4.60 (d, J = 
9.5 Hz, 1H, C-CH2-O), 4.72 (d, J = 5.5 Hz, 1H, C-CH-CH). 
13C-NMR (125 MHz, CDCl3): 26.1, 26.2, 26.7, 27.3, 60.2, 70.1, 76.0, 78.1, 104.2, 
110.8, 114.0, 197.1. 
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5.2.3 Synthesis of bis-protected phytyl hydroquinones 
 
(7R,11R,E)-1-bromo-3,7,11,15-tetramethylhexadec-2-ene (126) 
 
To a 0 °C cooled solution of 6.00 g 
natural E-phytol (127) (20.2 mmol, 
1.0 eq.) in 150 ml dry THF was slowly added 2.10 mL PBr3 (22.3 mmol, 1.1 eq.). The 
reaction mixture was stirred for 15 min at 0 °C. The reaction was quenched with 
saturated NaHCO3 and the mixture was extracted with ether (3x). The combined 
organic phases were dried over Na2SO4 and the solvent was removed in vacuo. The 
residue was filtered through a pad of silica gel (ether) to yield 7.10 g (19.7 mmol, 
98%) of a light yellow oil. 
 
1H-NMR (400 MHz, CDCl3): 0.84 (d, J = 6.7 Hz, 3H, C7/11-CH3), 0.85 (d, J = 6.7 Hz, 
3H, C7/11-CH3), 0.86 (d, J = 6.7 Hz, 6H, C15-CH3), 1.00-1.45 (m, 18H, H5-14), 1.54 
(sept, J = 6.7 Hz, 1H, H15), 1.71 (d, J = 1.2 Hz, 3H, C3-CH3), 2.02 (t, J = 7.6 Hz, 2H, 
H4), 4.03 (d, J = 8.5 Hz, 2H, H1), 5.52 (m, 1H, H2).  
13C-NMR (100 MHz, CDCl3): 16.3, 20.1, 20.2, 23.0, 23.1, 24.9, 25.2, 25.4, 28.4, 30.2, 
33.1, 33.2, 36.9, 37.7, 37.75, 37.83, 39.8, 40.2, 120.7, 144.6. 
 
1,4-bis(methoxymethoxy)-2,3,5-trimethylbenzene (120) 
 
5.00 g trimethylhydroquinone (26) (32.9 mmol, 1.0) 
was dissolved in 100 mL dry DMF. The solution was 
cooled to 0 °C and 3.42 g NaH (60% in mineral oil) 
(85.4 mmol, 2.6 eq.) were carefully added. The mixture 
was stirred for 15 min at 0 °C. Then a solution of 6.88 g Chloromethyl methyl ether 
(85.4 mmol, 2.6 eq.) were added dropwise. The mixture was stirred for 3 h at r.t. The 
reaction was quenched with H2O, and the mixture was extracted with ether (3x). The 
combined organic phases were washed with brine and dried over Na2SO4. 
Chromatography (SiO2, hexane/EtOAc = 5:1) afforded 7.28 g (30.3 mmol, 92%) of a 
colourless oil. 
 
TLC (SiO2, hexane/EtOAc = 5:1): Rf = 0.35. 
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1H-NMR (500 MHz, CDCl3): 2.12 (s, 3H, C-CH3), 2.19 (s, 3H, C-CH3), 2.25 (s, 3H, C-
CH3), 3.47 (s, 3H, O-CH3), 3.59 (s, 3H, O-CH3), 4.87 (s, 2H, CH2), 5.11 (s, 2H, CH2), 
6.74 (s, 1H, CH). 
13C-NMR (125 MHz, CDCl3): 12.5, 13.7, 17.3, 56.2, 57.7, 95.4, 99.6, 114.6, 114.6, 
125.0, 128.7, 131.1, 149.3, 151.7. 
Ms (EI): m/z (%) = 240.1 ([M+], 27), 195.1 (15), 45.0 (100). 
EA: calculated for C13H20O4: C 64.98, H 8.39; found: C 64.89, H 8.31. 
 
1,4-bis(methoxymethoxy)-2,3,5-trimethyl-6-((7R,11R,E)-3,7,11,15-
tetramethylhexadec-2-enyl)benzene (121) 
 
To a solution of 
15.7 mL n-BuLi 
(1.6 M in hexane) 
(25.2 mmol, 1.1 
eq.) in 74 mL dry 
Et2O was added at 0 °C 3.78 mL TMEDA (25.2 mmol, 1.1 eq.) together with 5.50 g 
protected hydroquinone 120 (22.9 mmol, 1.0 eq.). The mixture was stirred for 2.5 h at 
0 °C and then cooled to -20 °C. 328 mg CuBr (2.29 mmol, 0.1 eq.) followed by a 
solution of 6.40 g phytylbromide (126) (17.8 mmol, 0.8 eq.) in 5 mL dry Et2O were 
added. The reaction mixture was stirred for 4 h at r.t. The reaction was quenched 
with saturated NaHCO3 and the mixture was extracted with ether and the combined 
organic phases were dried over Na2SO4. Chromatography (SiO2, hexane/EtOAc = 
20:1) afforded 5.89 g (11.4 mmol, 64%) of a colourless oil. 
 
TLC (SiO2, hexane/EtOAc = 20:1) Rf = 0.22. 
1H-NMR (400 MHz, CDCl3): 0.82 (d, J = 6.6 Hz, 3H, C13/17-CH3), 0.83 (d, J = 6.6 Hz, 
3H, C13/17-CH3), 0.86 (d, J = 6.6 Hz, 6H, C21-CH3), 0.94-1.43 (m, 18H, 
H11/12/13/14/15/16/17/18/19/20), 1.51 (sept, J = 6.6 Hz, 1H, H21), 1.73 (s, 3H, C9-CH3), 1.93 (t, 
J = 7 Hz, 2H, H10), 2.18 (s, 3H, C2/3/6-CH3), 2.19 (s, 3H, C2/3/6-CH3), 2.20 (s, 3H, 
C2/3/6-CH3), 3.37 (d, J = 6.1 Hz, 2H, H7), 3.59 (s, 3H, O-CH3), 3.61 (s, 3H, O-CH3), 
4.86 (s, 2H, O-CH2-O), 4.88 (s, 2H, O-CH2-O), 5.02 (t, J = 6.1 Hz, 1H, H8).    
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13C-NMR (100 MHz, CDCl3): 13.5, 14.0, 14.1, 16.7, 20.1, 23.0, 23.1, 24.9, 25.2, 25.8, 
27.0, 28.4, 33.1, 33.2, 37.2, 37.7, 37.8, 37.9, 39.8, 40.4, 57.9, 58.0, 99.8, 100.2, 
123.2, 128.5, 128.6, 128.9, 132.4, 136.0, 150.7, 151.3. 
Ms (EI): m/z (%) = 518.4 ([M+], 34), 486.4 (20), 441.4 (100). 
EA: calculated for C33H58O4: C 76.40, H 11.27; found: C 76.26, H 11.08. 
 
2,3,5-trimethyl-6-((7R,11R,E)-3,7,11,15-tetramethylhexadec-2-enyl)cyclohexa-
2,5-diene-1,4-dione (122) 
 
To a solution of 500 mg 
alkene 121 (964 μmol, 1.0 
eq.) in 30 mL MeCN was 
added a solution of 1.04 g 
CAN (1.90 mmol, 2.0 eq.) in 3 mL H2O. The reaction mixture was stirred for 1 h at r.t. 
H2O was added and the mixture was extracted with DCM (3x). The combined organic 
phases were dried over Na2SO4. Chromatography (SiO2, hexane/EtOAc = 15:1) 
afforded 351 mg (819 μmol, 85%) of a yellow oil. 
 
TLC (SiO2, hexane/EtOAc = 10:1): Rf = 0.46. 
1H-NMR (500 MHz, CDCl3): 0.82 (d, J = 6.3 Hz, 3H, C13/17-CH3), 0.83 (d, J = 6.6 Hz, 
3H, C13/17-CH3), 0.86 (d, J = 6.6 Hz, 6H, C21-CH3), 0.95-1.43 (m, 18H, 
H11/12/13/14/15/16/17/18/19/20), 1.51 (sept, J = 6.6 Hz, 1H, H21), 1.72 (s, 3H, C9-CH3), 1.92 
(m, 2H, H10), 2.01 (s, 6H, C2/3-CH3), 2.02 (s, 3H, C6-CH3), 3.19 (d, J = 7.0 Hz, 2H, 
H7), 5.02 (t, J = 7.0 Hz, 1H, H8).  
13C-NMR (125 MHz, CDCl3): 12.4, 12.59, 12.61, 16.4, 19.94, 19.96, 22.8, 22.9, 24.7, 
25.0, 25.5, 25.8, 28.2, 32.9, 33.0, 36.9, 37.51, 37.59, 37.64, 39.6, 40.2, 119.4, 137.7, 
140.47, 140.54, 140.58, 143.5, 187.3, 188.2. 
Ms (EI): m/z (%) = 428.4 ([M+], 100), 203.1 (52), 176.1 (39), 165.1 (45). 
EA: calculated for C29H48O2: C 81.25, H 11.29; found: C 81.22, H 11.13. 
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2,3,5-trimethyl-6-((7R,11R,E)-3,7,11,15-tetramethylhexadec-2-enyl)benzene-1,4-
diol (123) 
 
To 1.50 g of quinone 122 
(3.50 mmol, 1.0 eq.) in 
100 mL of THF was 
added a large excess of 
Na2S2O4. H2O (ca. 70 mL) was added until all Na2S2O4 was dissolved. The 
characteristic yellow colour of the quinone disappeared immediately and the reaction 
was stirred at r.t. for 15 min to ensure completion. The mixture was then poured into 
a 1:1 mixture of DCM and H2O and extracted with three portions of DCM. The 
combined organic phases were washed with brine, dried over Na2SO4 and 
concentrated under vacuo to give 1.42 g of the crude title compound as a white waxy 
solid. The crude hydroquinone was used directly used for subsequent reactions to 
prevent the facile oxidation to the starting quinone 122. 
 
(2,3,5-trimethyl-6-((7R,11R,E)-3,7,11,15-tetramethylhexadec-2-enyl)-1,4-
phenylene)bis(oxy)bis(triisopropylsilane) (124) 
 
To a solution of 
425 mg hydro-
quinone 123 (987 
μmol, 1.0 eq.) in 
10 mL dry DMF 
was slowly added 
89 mg of NaH (60% in mineral oil) (2.23 mmol, 2.3 eq.) at 0 °C. The mixture was 
stirred for 20 min at 0 °C. To the resultant dark solution was then added dropwise 
472  μL of chlorotriisopropylsilane (2.23 mmol, 2.3 eq.). The mixture was stirred for 
2 h at 0 °C. The reaction was quenched with H2O and the mixture was extracted with 
ether (3x). The combined organic phases were dried over Na2SO4. Chromatography 
(SiO2, hexane/EtOAc = 60:1) afforded 619 mg (832 μmol, 84%) of a colourless oil. 
 
TLC (SiO2, hexane/EtOAc = 40:1): Rf = 0.62. 
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1H-NMR (400 MHz, CDCl3): 0.82 (d, J = 6.5 Hz, 3H, C13/17-CH3), 0.84 (d, J = 6.5 Hz, 
3H, C13/17-CH3), 0.86 (d, J = 6.6 Hz, 6H, C21-CH3), 0.95-1.43 (m, 24H, 
H11/12/13/14/15/16/17/18/19/20 +CHTips), 1.07 (d, J = 7.4 Hz, 36H, CH3 Tips), 1.51 (sept, J = 
6.6 Hz, 1H, H21), 1.68 (s, 3H, C9-CH3), 1.90 (t, J = 7.3 Hz, 2H, H10), 2.10 (s, 3H, 
C2/3/6-CH3), 2.13 (s, 6H, C2/3/6-CH3), 3.29 (d, J = 5.5 Hz, 2H, H7), 4.95 (t, J = 5.5 Hz, 
1H, H8).  
13C-NMR (100 MHz, CDCl3): 14.29, 14.35, 14.40, 14.7, 14.8, 16.5, 18.2, 18.3, 19.95, 
19.97, 22.9, 23.0, 24.7, 25.0, 25.6, 27.3, 28.2, 32.98, 33.03, 36.9, 37.5, 37.6, 37.7, 
39.6, 40.0, 124.0, 124.8, 125.1, 125.2, 128.9, 135.0, 147.1, 147.7.    
Ms (EI): m/z (%) = 742.6 ([M+], 100), 433.4 (29). 
EA: calculated for C47H90O2Si2: C 75.94, H 12.20; found: C 75.95, H 12.04. 
 
4-methoxy-2,3,5-trimethylphenol (128) 
 
To a 0°C cooled solution of 5.00 g trimethylhydroquinone (26) 
(32.9 mmol, 1.3 eq.) in 70 mL abs. DMF 3.42 g of NaH (60% in 
mineral oil) (85.4 mmol, 3.2 eq.) were carefully added. The mixture 
was stirred for 30 min at 0 °C. 1.63 mL MeI (26.3 mmol, 1.0 eq.) 
was added dropwise. The mixture was stirred for 1h at 0 °C. The reaction was 
quenched with H2O followed by saturated NH4Cl. The mixture was extracted with 
ether (3x) and the combined organic phases were washed with brine and dried over 
Na2SO4. Chromatography (SiO2, hexane/EtOAc = 4 : 1) afforded 2.33 g (14.0 mmol, 
53%) of an orange oil. 
 
 TLC (SiO2, hexane/EtOAc = 4 : 1): Rf = 0.27. 
1H-NMR (500 MHz, CDCl3): 2.13  (s, 3H, Car-CH3), 2.20 (s, 3H, Car-CH3), 2.22 (s, 3H, 
Car-CH3), 3.65 (s, 3H, O-CH3), 4.60 (br s, 1H, OH), 6.46 (s, 1H, Car-H). 
13C-NMR (125 MHz, CDCl3): 12.0(Car-CH3), 12.8 (Car-CH3), 16.1 (Car-CH3), 60.3 (O-
CH3), 114.6 (Car-H), 121.1 (Car-CH3), 128.5 (Car-CH3), 130.8 (Car-CH3), 149.5 (Car-O), 
150.7 (Car-O). 
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2-methoxy-1,3,4-trimethyl-5-((7R,11R,E)-3,7,11,15-tetramethylhexadec-2-
enyloxy)benzene (129) 
 
330 mg of 4-methoxy-
2,3,5-trimethylphenol 
(128) (1.96 mmol,1.0 eq.) 
were dissolved in 50 mL 
abs. DMF. The solution was cooled to 0°C and 111 mg NaH (60% in mineral oil) 
(2.78 mmol, 1.4 eq.) were carefully added. The suspension was stirred for 25 min. at 
0°C. Then a solution of 845 mg of phytylbromide (2.35 mmol, 1.2 eq.) in 10 ml abs. 
DMF was added dropwise. The mixture was stirred for 2h at 0°C. The reaction was 
quenched with water and extracted with ether (3x). The combined organic phases 
were dried over Na2SO4. Chromatography (SiO2, hexane/EtOAc = 40:1) gave 801 mg 
(1.80 mmol, 92%) of a light yellow oil. 
  
TLC (SiO2, hexane/EtOAc = 20 : 1): Rf = 0.40. 
1H-NMR (400 MHz, CDCl3): 0.84 (d, 3H, J = 3.7 Hz, C13/17-CH3), 0.86 (d, 3H, J = 
3.7 Hz, C13/17-CH3), 0.87 (d, 6H, J = 6.6 Hz, C21-CH3), 1.00-1.47 (m, 18H, 
H11/12/13/14/15/16/17/18/19/20), 1.51 (sept, 1H, J = 6.6 Hz, H21), 1.70 (s, 3H, C9-CH3), 2.03 (t, 
2H, J = 7.4 Hz, H10), 2.12 (s, 3H, C2/3/5-CH3), 2.19 (s, 3H, C2/3/5-CH3), 2.26 (s, 3H, 
C2/3/5-CH3), 3.65 (s, 3H, O-CH3),  4.47 (d, 2H, J = 6.4 Hz, H7), 5.48 (t, 1H, J = 6.4 Hz, 
H8), 6.54 (s, 1H, H5). 
13C-NMR (100 MHz, CDCl3): 12.46, 13.09, 16.69, 16.92, 20.14, 20.16, 23.04, 23.13, 
24.88, 25.21, 25.49, 28.39, 33.09, 33.20, 37.03, 37.70, 37.78, 37.84, 39.78, 40.27, 
60.54, 66.23, 112.50, 120.55, 124.71, 127.98, 130.94,140.97, 150.97, 153.28.  
MS (EI): m/z (%) = 444.4 ([M+], 1), 166.1 (100), 151.1 (15). 
EA: calculated for C30H52O2: C 81.02, H 11.78; found: C 80.77, H 11.50. 
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4-methoxy-2,3,5-trimethyl-6-((7R,11R,E)-3,7,11,15-tetramethylhexadec-2-
enyl)phenol (130) 
 
100 mg of ether 129 
(225 μmol, 1.0 eq.) were 
dissolved in 3 mL abs. 
DCM. At -30 °C 85 μL of 
boron trifluoride ethyl etherate (675 μmol, 3.0 eq.) were added to the solution. The 
mixture was stirred for 10 min at -30 °C. The cooling bath was removed and wet 
DCM followed by water was added. The phases were separated and the aqueous 
phase was further extracted with DCM. Chromatography (SiO2, hexane/EtOAc = 
20:1) gave 69 mg (155 μmol, 69%) of a colourless oil.  
 
TLC (SiO2, hexane/EtOAc = 20:1): Rf = 0.40. 
1H-NMR (400 MHz, CDCl3): 0.83 (d, 3H, J = 6.6 Hz, C13/17-CH3), 0.84 (d, 3H, J = 
6.6 Hz, C13/17-CH3), 0.86 (d, 6H, J = 6.6 Hz, C21-CH3), 1.00-1.47 (m, 18H, 
H11/12/13/14/15/16/17/18/19/20), 1.51 (sept, 1H, J = 6.6 Hz, H21), 1.81 (s, 3H, C9-CH3), 1.99 (t, 
2H, J = 7.3 Hz, H10), 2.14 (s, 3H, C2/3/6-CH3), 2.20 (s, 3H, C2/3/6-CH3), 2.23 (s, 3H, 
C2/3/6-CH3), 3.36 (d, 2H, J = 6.8 Hz, H7), 3.63 (s, 3H, O-CH3), 4.96 (s, 1H, OH), 5.13 
(m, 1H, H8). 
13C-NMR (100 MHz, CDCl3): 12.45, 12.82, 13.06, 14.53, 16.61, 23.03, 23.07, 23.13, 
24.87, 25.21, 25.71, 26.79, 28.39, 32.00, 33.08, 33.19, 37.09, 37.70, 37.78, 37.84, 
39.78, 40.43, 60.78, 121.76, 121.84, 123.82, 126.88, 128.52, 139.08, 149.19, 
150.84. 
MS (EI): m/z (%) = 445.4 (25), 444.4 ([M+], 77), 179.1 (100). 
EA: calculated for C30H52O2: C 81.02, H 11.78; found: C 81.05, H 11.51. 
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1-(benzyloxy)-4-methoxy-2,3,5-trimethyl-6-((7R,11R,E)-3,7,11,15-
tetramethylhexadec-2-enyl)benzene (131) 
 
162 mg of phenol 130 
(365 μmol, 1.0 eq.) were 
dissolved in 2 mL abs. 
DMF. At 0 °C 16 mg 
NaH (60% in mineral oil) 
(400 μmol, 1.1 eq.) were added. The mixture was stirred for 15 min at 0 °C. After 
52 μL benzyl bromide (440 μmol, 1.2 eq.) were added. The mixture was stirred for 
2 h at 0 °C. The reaction was quenched with H2O and the mixture was extracted with 
ether (3x). The combined organic phases were dried over Na2SO4. Chromatography 
(SiO2, hexane/EtOAc = 40 : 1) afforded 153 mg (286 μmol, 78%) of a light yellow oil. 
 
TLC (SiO2, hexane/EtOAc = 20 : 1): Rf = 0.34. 
1H-NMR (400 MHz, CDCl3): 0.81 (d, 3H, J = 6.8 Hz, C13/17-CH3), 0.83 (d, 3H, J = 
6.8 Hz, C13/17-CH3), 0.86 (d, 6H, J = 6.6 Hz, C21-CH3), 0.95-1.45 (m, 18H, 
H11/12/13/14/15/16/17/18/19/20), 1.52 (sept, 1H, J = 6.6 Hz, H21), 1.68 (s, 3H, C9-CH3), 1.93 
(m, 2H, H10), 2.20 (s, 6H, C2/3/6-CH3), 2.22 (s, 3H, C2/3/6-CH3), 3.41 (d, 2H, J = 5.5 Hz, 
H7), 3.66 (s, 3H, O-CH3), 4.72 (s, 2H, CbenzylH2), 5.08 (m, 1H, H8), 7.33 (m, 1H, Hp, 
benzyl), 7.39 (t, 2H, J = 7.2 Hz, Hm, benzyl), 7.48 (d, 2H, J = 7.2 Hz, Ho, benzyl). 
13C-NMR (100 MHz, CDCl3): 12.65, 13.17, 13.48, 16.68, 20.12, 20.14, 23.04, 23.13, 
24.88, 25.20, 25.81, 26.69, 28.38, 33.11, 33.19, 37.14, 37.70, 37.80, 37.84, 39.78, 
40.37, 60.55, 75.57, 123.50, 127.95, 128.17, 128.28, 128.52, 128.66, 128.85, 
132.41, 136.09, 138.31, 151.82, 153.61.    
MS (EI): m/z (%) = 534.4 ([M+], 36), 256.1 (17), 217 (20), 191.1 (30), 179.1 (100). 
EA: calculated for C37H58O2: C 83.09, H 10.93; found: C 82.90, H 10.81. 
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tribenzyl(4-methoxy-2,3,5-trimethyl-6-((7R,11R,E)-3,7,11,15-tetramethylhexadec-
2-enyl)phenoxy)silane (133) 
 
390 mg of phenol 130 
(877 μmol, 1.0 eq.) were 
dissolved in 8 mL abs. 
DMF. At 0 °C 45 mg 
NaH (60% in mineral oil) 
(1.14 mmol, 1.3 eq.) 
were added. The 
mixture was stirred for 30 min at 0 °C. Then 384 mg chlorotribenzylsilane 
(1.14 mmol, 1.3 eq.) were added. The mixture was stirred for 2 h at 0 °C. The 
reaction was quenched with H2O and the mixture was extracted with ether (3x). The 
combined organic phases were dried over Na2SO4. Chromatography (SiO2, 
hexane/TBME = 20:1) afforded 521 mg (699 μmol, 80%) of a colourless oil. 
 
TLC (SiO2, hexane/TBME = 20:1): Rf = 0.32. 
1H-NMR (500 MHz, CDCl3): 0.82 (d, J = 6.6 Hz, 3H, C13/17-CH3), 0.83 (d, J = 6.6 Hz, 
3H, C13/17-CH3), 0.87 (d, J = 6.7 Hz, 6H, C21-CH3), 0.96-1.45 (m, 18H, 
H11/12/13/14/15/16/17/18/19/20), 1.52 (sept, J = 6.6 Hz, 1H, H21), 1.64 (s, 3H, C9-CH3),1.89 (s, 
3H, C2/3/6-CH3), 1.91-1.98 (m, 2H, H10), 2.15 (s, 3H, C2/3/6-CH3), 2.16 (s, 3H, C2/3/6-
CH3), 2.34 (s, 6H, CH2, benzyl), 3.24 (d, J = 5.5 Hz, 2H, H7), 3.68 (s, 3H, O-CH3), 4.91 
(m, 1H, H8), 6.83 (d, J = 7.2 Hz, 6H, Ho, benzyl), 7.07 (t, J = 7.3 Hz, 3H, Hp, benzyl), 7.12 
(t, J = 7.3 Hz, 6H, Hm, benzyl). 
13C-NMR (125 MHz, CDCl3): 12.50, 13.09, 14.65, 16.44, 19.86, 19.89, 22.78, 22.88, 
23.86, 24.64, 24.95, 25.68, 27.12, 28.13, 32.88, 32.95, 37.01, 37.44, 37.56, 37.60, 
39.52, 40.07, 60.50, 123.06, 124.71, 125.87, 127.72, 127.86, 128.33, 129.28, 
129.55, 136.32, 137.81, 148.06, 151.98. 
Ms (EI): m/z (%) = 744.5 ([M+], 43), 388.2 (33), 387.2 (100). 
EA: calculated for C51H72O2Si: C 82.20, H 9.74; found: C 82.25, H 9.73. 
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4-(tert-butyldiphenylsilyloxy)-2,3,6-trimethylphenol  (134) 
 
To a solution of 2.20 g 2,3,5-trimethylbenzene-1,4-diol (26) (14.4 
mmol, 1.0 eq.) and 3.90 g imidazole (57.8 mmol, 4.0 eq.) in 20 mL 
DMF  at -30°C, was added dropwise a solution of 4.5 mL DPSCl 
(17.3 mmol, 1.2 eq.) in 14 mL DMF. The mixture was allowed to 
warm up to room temperature and stirred for 4 h. The reaction was 
quenched with H2O and extracted with DCM (3x). The combined 
organic phases were washed with H2O, brine, dried over Na2SO4, 
and evaporated to dryness. The crude oil was purified by column chromatography 
(SiO2, hexane/DCM = 7:3) to afford 5.29 g (13.5 mmol, 94%) of a colourless oil.  
 
TLC (SiO2, hexane/EtOAc = 10:1): Rf = 0.19. 
1H-NMR (400 MHz, CDCl3): 1.10 (s, 9H, tBu), 1.86 (s, 3H, C6-CH3), 2.19 (s, 3H, C2-
CH3), 2.30 (s, 3H, C3-CH3), 4.16 (s, 1H, OH), 6.08 (s, 1H, H5), 7.38 (m, 6H, Hm/Hp 
DPS-), 7.73 (dd, 4H, J = 7.9, 1.3 Hz, Ho DPS-).  
13C-NMR (100 MHz, CDCl3): 12.8 (C3-CH3), 13.4 (C2-CH3), 16.2 (C6-CH3), 20.0 (C-
(CH3)3), 27.1 (C-(CH3)3), 118.0 (C5), 120.1 (C3), 123.6 (C2), 125.5 (C6), 128.1 (Cm, 
DPS-), 130.1 (Cp, DPS-), 133.8 (CSi, DPS-), 135.9 (Co, DPS), 146.2 (C4), 147.3 (C1).  
MS (EI): m/z (%) = 390.2 ([M+]).  
EA: calculated for C25H30O2Si: C 76.88, H 7.74; found: C 76.92, H 7.79. 
IR(neat) νmax 3576, 2930, 2856, 1472, 1427, 1326, 1233, 1189, 1107, 1082, 876, 
822, 698 cm-1. 
 
tert-butyldiphenyl(2,3,5-trimethyl-4-((7R,11R,E)-3,7,11,15-tetramethylhexadec-2-
enyloxy)phenoxy)silane (135)138 
 
To a 0 °C cooled suspension of 
350 mg NaH (60% in mineral 
oil) (8.75 mmol, 1.2 eq.) in 
20 mL dry DMF was added a 
solution of 2.88 g mono-
protected hydroquinone 134 (7.36 mmol, 1.0 eq.) in 20 mL DMF. The mixture was 
stirred for 30 min at 0 °C and then a solution of 2.94 g phytylbromide (126) 
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(8.18 mmol, 1.1 eq.) in 20 mL DMF was added dropwise. The solution was allowed to 
warm up to r.t. and stirred for 5 h. The reaction was quenched with saturated 
NaHCO3 and extracted with DCM (3x). The combined organic phases were dried 
over Na2SO4, evaporated to dryness and the residue purified by column 
chromatography (SiO2, hexane/EtOAc = 97:3) to afford 4.29 g (6.40 mmol, 87%) of a 
colourless oil.  
 
TLC (SiO2, hexane/EtOAc = 20:1): Rf = 0.52. 
1H-NMR (500 MHz, CDCl3): 0.83 (d, J = 4.1 Hz, 3H, C13/17-CH3), 0.85 (d, J = 4.1 Hz, 
3H, C13/17-CH3), 0.87 (d, J = 6.9 Hz, 6H, C21-CH3), 0.99-1.07 (m, 5H, H12/14/16/18), 1.10 
(s, 9H, tBu), 1.14 (m, 2H, H20), 1.17-1.48 (m, 9H, H11/12/14/15/16/18/19), 1.38 (m, 2H, 
H13/17), 1.53 (sept, J = 6.6 Hz, 1H, H21), 1.62 (s, 3H, C9-CH3), 1.89 (s, 3H, C6-CH3), 
2.02 (m, 2H, H10), 2.21 (s, 3H, C2-CH3), 2.27 (s, 3H, C3-CH3), 4.17 (d, J = 6.9 Hz, 2H, 
H7), 5.52 (t, J = 6.9 Hz, 1H, H8), 6.10 (s, 1H, H5), 7.35 (m, 4H, Hm DPS-), 7.41 (m, 
2H, Hp DPS-), 7.70 (d, J = 6.9 Hz, 4H, Ho DPS-).  
13C-NMR (125 MHz, CDCl3): 13.0 (C3-CH3), 13.3 (C2-CH3), 16.2 (C6-CH3), 16.4 (C9-
CH3), 19.7 (C-(CH3)3), 19.8 (C13/17-CH3), 22.7 (C22), 24.5 (C15/19), 24.8 (C15/19), 25.1 
(C11), 26.7 (C-(CH3)3), 28.0 (C21), 32.7 (C13/17), 32.8 (C13/17), 36.7 (C12), 37.3 
(C14/16/18), 37.4 (C14/16/18), 39.4 (C20), 40.0 (C10), 69.3 (C7),  118.0 (C5), 120.2 (C8), 
125.0 (C3), 127.6 (C6), 127.8 (Cm, DPS-), 129.7 (Cp, DPS-), 130.5 (C2), 133.3 (CSi, 
DPS-), 135.5 (Co, DPS), 140.8 (C9), 149.2 (C4), 149.7 (C1).  
MS (EI): m/z (%) = 668.5 ([M+], 0.16), 390.2 (100), 333.1 (63), 255.1 (13).  
EA: calculated for C45H68O2Si: C 80.78, H 10.24; found: C 80.64, H 10.22.  
IR(neat) νmax 2926, 2857, 1473, 1428, 1377, 1322, 1220, 1113, 1086, 981, 886, 822, 
700 cm-1. 
 
4-(tert-butyldiphenylsilyloxy)-2,3,6-trimethyl-5-((7R,11R,E)-3,7,11,15-
tetramethylhexadec-2-enyl)phenol (136)138 
 
To a -30 °C cooled 
solution of  4.29 g alkene 
135 (6.41 mmol, 1.0 eq.) 
in 150 mL DCM, was 
added dropwise 2.5 mL of BF3·Et2O (9.62 mmol, 1.5 eq.). The yellow solution was 
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stirred for 10 min at -30 °C and then quenched by the addition of H2O. The mixture 
was warmed up to room temperature and extracted with DCM (3x).The combined 
organic phases were dried over Na2SO4, evaporated to dryness and the residue was 
purified by column chromatography (SiO2, hexan/CH2Cl2 = 75:25) to afford 2.57 g 
(3.85 mmol, 60%) of a slight yellow oil.  
 
TLC (SiO2, hexane/DCM = 7:3): Rf = 0.23. 
1H-NMR (500 MHz, CDCl3): 0.82 (d, J = 6.6 Hz, 3H, C13/17-CH3), 0.84 (d, J = 6.6 Hz, 
3H, C13/17-CH3), 0.86 (d, J = 6.6 Hz, 6H, C21-CH3), 0.99-1.03 (m, 4H, H12/14/16/18), 1.10 
(s, 9H, tBu), 1.13 (m, 2H, H20), 1.17-1.31 (m, 10H, H11/12/14/15/16/18/19), 1.31-1.43 (m, 
2H, H13/17), 1.48 (s, 3H, C9-CH3, E-isomer), 1.52 (sept, J = 6.6 Hz, 1H, H21), 1.81 (s, 
3H, C3-CH3), 1.83 (m, 2H, H10), 2.03 (s, 3H, C2-CH3), 2.06 (s, 3H, C6-CH3), 3.26 (d, 
J = 5.4 Hz, 2H, H7), 4.29 (s, 1H, OH), 4.84 (t, J = 5.7 Hz, 1H, H8), 7.31 (m, 4H, Hm 
DPS-), 7.39 (m, 2H, Hp DPS-), 7.67 (d, J = 6.6 Hz, 4H, Ho DPS-).  
13C-NMR (125 MHz, CDCl3): 12.3 (C6-CH3), 12.6 (C2-CH3), 16.0 (C3-CH3), 16.3 (C9-
CH3), 19.8 (C13/17-CH3), 20.4 (C-(CH3)3), 22.7 (C22), 22.8 (C22), 24.6 (C11/15/19), 24.9 
(C11/15/19), 25.4 (C11/15/19), 27.2 (C-(CH3)3), 27.4 (C7), 28.1 (C21), 32.8 (C13/17), 32.9 
(C13/17), 36.8 (C12/14/16/18), 37.4 (C12/14/16/18), 37.5 (C12/14/16/18), 37.6 (C12/14/16/18), 39.5 
(C20), 39.9 (C10), 120.2 (C6), 120.4 (C2), 123.5 (C8), 124.6 (C3), 127.5 (Cm, DPS-), 
128.8 (C5), 129.5 (Cp, DPS-), 134.8 (CSi, DPS-), 135.0 (C9), 135.3 (Co, DPS), 146.0 
(C4), 146.3 (C1).  
MS (EI): m/z (%) = 668.5 ([M+]).  
EA: calculated for C45H68O2Si: C 80.78, H 10.24; found: C 80.38, H 10.15.  
HPLC (Protonsil® 120-5-CN, heptane/isopropanol = 99.7:0.3, 0.4 mL/min, 220 nm): 
tE-isomer = 17.4 min (94.4%), tZ-isomer = 18.4 min (1.6%), E:Z ratio = 98.3:1.7. 
IR (neat): νmax 3465, 2926, 2856, 1462, 1428, 1376, 1251, 1190, 1112, 1086, 840, 
821, 701 cm-1. 
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tert-butyl(4-methoxy-2,3,5-trimethyl-6-((7R,11R,E)-3,7,11,15-
tetramethylhexadec-2-enyl)phenoxy)diphenylsilane (132)138  
 
To a 0 °C cooled 
suspension of 230 mg 
NaH (60% in mineral 
oil) (5.76 mmol, 1.5 
eq.) in 20 mL DMF was added a solution of 2.57 g phenol 136 (3.84 mmol, 1.0 eq.) in 
20 mL DMF. The mixture was stirred for 30 min at 0 °C and 500 μL MeI (7.68 mmol, 
2 eq.) were added dropwise. The solution was allowed to warm up to room 
temperature and stirred for 4 h. The reaction was quenched with saturated NaHCO3 
and extracted with DCM (3x). The combined organic phases were dried over 
Na2SO4, evaporated to dryness and the residue purified by column chromatography 
(SiO2, hexan/CH2Cl2 = 75:25) to afford 2.44 g (3.57 mmol, 93%) of a colourless oil. 
 
TLC (SiO2, hexane/EtOAc = 20:1): Rf = 0.51.  
1H-NMR (500 MHz, CDCl3): 0.82 (d, 3H, J = 6.6 Hz, C13/17-CH3), 0.84 (d, 3H, J = 6.6 
Hz, C13/17-CH3), 0.87 (d, 6H, J = 6.6 Hz, C21-CH3), 0.94-1.09 (m, 4H, H12/14/16/18), 1.10 
(s, 9H, tBu), 1.13 (m, 2H, H20), 1.17-1.35 (m, 10H, H11/12/14/15/16/18/19), 1.35-1.40 (m, 
2H, H13/17), 1.50 (s, 3H, C9-CH3, E-isomer), 1.51 (sept, 1H, J = 6.6 Hz, H21), 1.78 (s, 
3H, C3-CH3), 1.83 (m, 2H, H10), 2.05 (s, 3H, C2-CH3), 2.11 (s, 3H, C6-CH3), 3.25 (d, 
2H, J = 5.7 Hz, H7), 3.61 (s, 3H, CH3O), 4.86 (t, 1H, J = 5.4 Hz, H8), 7.31 (m, 4H, Hm 
TBDPS-), 7.38 (m, 2H, Hp DPS-), 7.66 (d, 4H, J = 6.9 Hz, Ho DPS-). 
13C-NMR (125 MHz, CDCl3): 12.4 (C6-CH3), 12.9 (C2-CH3), 15.8 (C3-CH3), 16.1 (C9-
CH3), 19.8 (C13/17-CH3), 20.3 (C-(CH3)3), 22.6 (C22), 22.7 (C22), 24.5 (C11/15/19), 24.8 
(C11/15/19), 25.3 (C11/15/19), 27.1 (C-(CH3)3), 27.4 (C7), 28.0 (C21), 32.7 (C13/17), 32.8 
(C13/17), 36.7 (C12/14/16/18), 37.3 (C12/14/16/18), 37.4 (C12/14/16/18), 37.5 (C12/14/16/18), 39.4 
(C20), 39.8 (C10), 60.3 (CH3O), 123.2 (C8), 124.9 (C3), 127.4 (C6), 127.5 (C2), 127.6 
(Cm, TBDPS-), 129.1 (C5), 129.4 (Cp, DPS-), 134.6 (CSi, DPS-), 134.9 (C9), 135.2 (Co, 
TBDPS), 148.2 (C4), 151.1 (C1).  
MS (EI): m/z (%) = 682.5 ([M+], 9), 359.1 (100).  
EA: calculated for C46H70O2Si: C 80.88, H 10.33; found: C 80.93, H 10.27.  
IR (neat): νmax 2926, 2857, 1461, 1405, 1246, 1112, 1087, 886, 701 cm-1. 
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5.2.4 Epoxidation of bis-protected phytyl hydroquinone substrates 
 
(2,3,5-trimethyl-6-((3-methyl-3-((4R,8R)-4,8,12-trimethyltridecyl)oxiran-2-
yl)methyl)-1,4-phenylene)bis(oxy)bis(triisopropylsilane) (149) 
 
50 mg alkene 124 
(67.3 μmol, 1.0 
eq.) was dissolved 
in 1 mL of dry 
ether. At 0 °C 
14 mg of mCPBA 
(80.7 μmol, 1.2 eq.) were added. The mixture was stirred over night at r.t. The 
reaction was quenched with 1 M NaOH, and the mixture was extracted with ether 
(3x). The combined organic phases were washed with H2O and dried over Na2SO4. 
Chromatography (SiO2, hexane/EtOAc = 40:1) afforded 40 mg (53 μmol, 78%) of a 
colourless oil. 
 
TLC (SiO2, hexane/EtOAc = 40:1): Rf = 0.22. 
1H-NMR (500 MHz, CDCl3): 0.81 (d, J = 6.6 Hz, 3H, C13/17-CH3), 0.83 (d, J = 6.6 Hz, 
3H, C13/17-CH3), 0.86 (d, J = 6.6 Hz, 6H, C21-CH3), 0.95-1.43 (m, 24H, 
H11/12/13/14/15/16/17/18/19/20 +CHTips), 1.06-1.10 (m, 36H, CH3 Tips),  1.36 (s, 3H, C9-
CH3),1.52 (sept, J = 6.6 Hz, 1H, H21), 2.13 (s, 6H, C2/3-CH3), 2.21 (s, 3H, C6-CH3), 
2.70-2.76 (m, 1H, H7), 2.73-2.76 (m, 1H, H8), 3.05 (dd, J = 13.9, 3.4 Hz, 1H, H7). 
13C-NMR (125 MHz, CDCl3): 14.2, 14.4, 14.7, 14.8, 15.0, 17.3, 18.1, 18.17, 18.20, 
19.8, 19.9, 22.6, 22.8, 22.9, 24.6, 24.9, 28.0, 28.1, 32.90, 32.94, 37.3, 37.4, 37.6, 
39.0, 39.5, 61.1, 64.1, 125.0, 125.3, 126.0, 126.1, 147.4, 147.8.  
HPLC (Chiralcel AD-H, n-heptane, 0.6 mL/min, 220 nm): t(2R) = 7.27 min (50%), t(2S) = 
8.31 min (50%).  
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3-(2-(benzyloxy)-5-methoxy-3,4,6-trimethylbenzyl)-2-methyl-2-((4R,8R)-4,8,12-
trimethyltridecyl)oxirane 
 
73 mg alkene 131 (136 
μmol, 1.0 eq.) was 
dissolved in 1 mL of dry 
ether. At 0 °C 35 mg 
mCPBA (205 μmol, 1.5 
eq.) were added. The mixture was stirred for 5 h at 0 °C. The reaction was quenched 
with 1 M NaOH, and the mixture was extracted with ether (3x). The combined organic 
phases were washed with H2O and dried over Na2SO4. Chromatography (SiO2, 
hexane/EtOAc = 20:1) afforded 64 mg (116 μmol, 85%) of a colourless oil. 
 
TLC (SiO2, hexane/EtOAc = 20:1): Rf = 0.17. 
1H-NMR (500 MHz, CDCl3): 0.80 (d, J = 6.6 Hz, 3H, C13/17-CH3), 0.83 (d, J = 6.6 Hz, 
3H, C13/17-CH3), 0.86 (d, J = 6.6 Hz, 6H, C21-CH3), 0.96-1.08 (m, 4H, H12/14/16/18), 
1.10-1.38 (m, 16H, H10/11/12/13/14/15/16/17/18/19/20), 1.32 (s, 3H, C9-CH3), 1.52 (sept, 1H, 
J=6.1 Hz, H21), 2.21 (s, 3H, C2/3/6-CH3), 2.23 (s, 3H, C2/3/6-CH3), 2.29 (s, 3H, C2/3/6-
CH3), 2.80-2.87 (m, 2H, H7/8), 2.99-3.06 (m, 1H, H7), 3.67 (s, 3H, CH3O), 4.73 (d, J = 
11.3 Hz, 1H, CH2 benzyl), 4.80 (d, J = 11.3 Hz, 1H, CH2 benzyl),  7.34 (t, J = 7.3 Hz, 
1H, Hp benzyl), 7.40 (t, J = 7.3 Hz, 2H, Hm benzyl), 7.49 (d, 4H, J = 7.3 Hz, Ho 
benzyl).   
13C-NMR (125 MHz, CDCl3): 12.97, 13.04, 13.35, 17.13, 19.73, 19.88, 22.77, 22.87, 
24.62, 24.94, 27.11, 28.12, 32.89, 32.92, 32.94, 37.11, 37.13, 37.43, 37.46, 37.56, 
39.04, 39.51, 60.29, 61.52, 63.88, 75.23, 127.71, 128.01, 128.23, 128.44, 128.64, 
129.06, 129.33, 137.83, 152.03, 153.46. 
HPLC (Chiralcel OD-H, heptane/isopropanol = 98:2, 0.6 mL/min, 220 nm): t(2R) = 
7.61 min (50%), t(2S) = 13.07 min (50%). 
MS (EI): m/z (%) = 550.4 ([M+], 29), 191.1 (33), 179.1 (100). 
EA: calculated for C37H58O3: C 80.67, H 10.61; found: C 80.60, H 10.50. 
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tribenzyl(4-methoxy-2,3,5-trimethyl-6-((3-methyl-3-((4R,8R)-4,8,12-
trimethyltridecyl)oxiran-2-yl)methyl)phenoxy)silane 
 
150 mg alkene 133 (201 
μmol, 1.0 eq.) was 
dissolved in 1 mL of dry 
ether. At 0 °C 45 mg 
mCPBA (262 μmol, 1.3 
eq.) were added. The 
mixture was stirred for 
5 h at 0 °C. The reaction was quenched with 1 M NaOH, and the mixture was 
extracted with ether (3x). The combined organic phases were washed with H2O and 
dried over Na2SO4. Chromatography (SiO2, hexane/TBME = 20:1) afforded 139 mg 
(183 μmol, 91%) of a colourless oil. 
 
TLC (SiO2, hexane/TBME = 20:1): Rf = 0.32. 
1H-NMR (500 MHz, CDCl3): 0.79 (d, J = 6.6 Hz, 3H, C13/17-CH3), 0.83 (d, J = 6.6 Hz, 
3H, C13/17-CH3), 0.86 (d, J = 6.6 Hz, 6H, C21-CH3), 0.94-1.40 (m, 18H, 
H11/12/13/14/15/16/17/18/19/20), 1.26 (s, 3H, C3-CH3),1.52 (sept, J = 6.6 Hz, 1H, H21), 1.96 (s, 
3H, C9-CH3), 2.16 (s, 3H, C2/6-CH3), 2.24 (s, 3H, C2/6-CH3), 2.36 (m, 6H, CH2 benzyl), 
2.56 (m, 1H, H7), 2.66 (m, 1H, H8), 2.87-2.94 (m, 1H, H7), 3.24 (d, J = 5.5 Hz, 2H, 
H7), 3.68 (s, 3H, O-CH3), 6.83 (d, J = 7.2 Hz, 6H, Ho, benzyl), 7.06 (t, J = 7.3 Hz, 3H, Hp, 
benzyl), 7.12 (t, J = 7.3 Hz, 6H, Hm, benzyl). 
13C-NMR (125 MHz, CDCl3): 13.17, 13.24, 14.81, 17.04, 17.07, 19.72, 19.73, 19.88, 
22.61, 22.65, 22.78, 22.87, 24.63, 24.65, 24.94, 27.87, 28.12, 32.89, 32.92, 32.95, 
37.25, 37.43, 37.49, 37.56, 28.89, 39.51, 60.49, 61.17, 63.49, 124.84, 125.86, 
126.85, 128.07, 128.38, 128.73, 129.26, 137.56, 148.50, 152.09. 
HPLC (Chiralcel AD-H, heptane/isopropanol = 99.8:0.2, 0.6 mL/min, 220 nm): t(2R) = 
13.00 min (50%), t(2S) = 15.27 min (50%). 
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tert-butyl(4-methoxy-2,3,5-trimethyl-6-((3-methyl-3-((4R,8R)-4,8,12-
trimethyltridecyl)oxiran-2-yl)methyl)phenoxy)diphenylsilane 
 
72 mg alkene 132 (105 
μmol, 1.0 eq.) was 
dissolved in 1 mL of dry 
ether. At 0 °C 27 mg 
mCPBA (173 μmol, 1.5 eq.) were added. The mixture was stirred for 5 h at 0 °C. The 
reaction was quenched with 1 M NaOH, and the mixture was extracted with ether 
(3x). The combined organic phases were washed with H2O and dried over Na2SO4. 
Chromatography (SiO2, hexane/EtOAc = 20:1) afforded 63 mg (90 μmol, 86%) of a 
colourless oil. 
 
TLC (SiO2, hexane/EtOAc = 20:1): Rf = 0.12. 
1H-NMR (500 MHz, CDCl3): 0.81 (d, J = 6.8 Hz, 3H, C13/17-CH3), 0.83 (d, J = 6.7 Hz, 
3H, C13/17-CH3), 0.86 (d, J = 6.6 Hz, 6H, C21-CH3), 0.94-1.09 (m, 4H, H12/14/16/18), 1.12 
(s, 9H, tBu), 1.13 (m, 2H, H20), 1.16-1.41 (m, 14H, H10/11/12/13/14/15/16/17/18/19), 1.17 (s, 
3H, C9-CH3), 1.52 (sept, J = 6.1 Hz, 1H, H21), 1.76 (s, 3H, C3-CH3), 2.04 (s, 3H, C2-
CH3), 2.23 (s, 3H, C6-CH3), 2.49 (m, 1H, H7), 2.76 (d, 1H, 5.7 Hz, H8), 3.22 (m, 1H, 
H7), 3.62 (s, 3H, CH3O), 7.32 (m, 4H, Hm DPS-), 7.40 (m, 2H, Hp DPS-), 7.66 (d, J = 
6.9 Hz, 4H, Ho DPS-).  
13C-NMR (125 MHz, CDCl3): 12.9 (C6-CH3), 13.2 (C2-CH3), 15.8 (C3-CH3), 16.1 (C9-
CH3), 19.6 (C13/17-CH3), 19.7 (C13/17-CH3), 20.3 (C-(CH3)3), 22.2 (C11), 22.6 (C22), 22.7 
(C22), 24.5 (C15/19), 24.8 (C15/19), 27.1 (C-(CH3)3), 27.9 (C7), 28.0 (C21), 32.8 (C13/17), 
37.1 (C12/14/16/18), 37.3 (C12/14/16/18), 37.4 (C12/14/16/18), 38.6 (C10), 39.4 (C20), 60.2 
(CH3O), 60.7 (C9), 63.9 (C8), 125.0 (C3), 126.4 (C6), 127.5 (C2), 127.6 (Cm, DPS-), 
128.5 (C5), 129.6 (Cp, DPS-), 134.3 (CSi, DPS-), 135.1 (Co, DPS), 148.5 (C4), 151.3 
(C1).  
MS (EI): m/z (%) = 698.5, 641.4.  
EA: calculated for C46H70O3Si: C 79.03, H 10.09; found: C 78.84, H 9.82.  
HPLC (Chiralcel AD-H, 0.1% iPrOH in n-heptane, 0.6 mL/min, 220 nm): t(2R,3R) = 7.9 
min (50 %), t(2S,3S) = 8.7 min (50 %). 
IR (neat): νmax 2926, 2858, 1461, 1404, 1246, 1111, 1086, 880, 701 cm-1.  
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Si
Si
O
Asymmetric Shi Epoxidation, General Procedure: 
 
To a solution of alkene (55 μmol, 1.0 eq) and catalyst ent-114 (or 114) (22 μmol, 0.4 
eq) in ACN:EtOH:CH2Cl2 (1:1:2, 200 μL) was added a buffer solution of 2M 
K2CO3/4.10-4 M EDTA (140 μL). The mixture was cooled down to 0°C and H2O2 (30% 
aq., 30 μL, 5.4 eq.) was added in one portion. The reaction was stirred at 0 °C for 
10h, and diluted with CH2Cl2 and H2O. The organic phase was extracted and the 
water phase further extracted with CH2Cl2 (2x). Combined organic phases were dried 
over Na2SO4, evaporated to dryness and the residue was purified by column 
chromatography on SiO2. 
 
(2,3,5-trimethyl-6-(((2R,3R)-3-methyl-3-((4R,8R)-4,8,12-trimethyltridecyl)oxiran-2-
yl)methyl)-1,4-phenylene)bis(oxy)bis(triisopropylsilane) 
 
 
 
 
 
 
 
Was obtained in 75% yield and with 82% de by following the general procedure 
employing ketone catalyst 114.  
 
(2S,3S)-3-(2-(benzyloxy)-5-methoxy-3,4,6-trimethylbenzyl)-2-methyl-2-((4R,8R)-
4,8,12-trimethyltridecyl)oxirane 
 
O
O
1
2
3 4
5
6 7
8
9 13 17 21
O
 
Was obtained in 75% yield and with 82% de by following the general procedure 
employing ketone catalyst ent-114.  
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tribenzyl(4-methoxy-2,3,5-trimethyl-6-(((2S,3S)-3-methyl-3-((4R,8R)-4,8,12-
trimethyltridecyl)oxiran-2-yl)methyl)phenoxy)silane 
 
 
 
 
 
 
 
Was obtained in 84% yield and with 89% de by following the general procedure 
employing ketone catalyst ent-114.  
 
tert-butyl(4-methoxy-2,3,5-trimethyl-6-(((2S,3S)-3-methyl-3-((4R,8R)-4,8,12-
trimethyltridecyl)oxiran-2-yl)methyl)phenoxy)diphenylsilane (147) 
MeO
ODPS
1
2
3 4
5
6 7
8
9 13 17 21
O
 
Was obtained in 81% yield and with 97% de by following the general procedure 
employing ketone catalyst ent-114.  
 
 
tert-butyl(4-methoxy-2,3,5-trimethyl-6-(((2R,3R)-3-methyl-3-((4R,8R)-4,8,12-
trimethyltridecyl)oxiran-2-yl)methyl)phenoxy)diphenylsilane (148) 
 
 
 
 
Was obtained in 80% yield and with 96% de by following the general procedure 
employing ketone catalyst 114.  
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5.2.5 Cyclisation of 149 to furan 150 
 
2-((6R,10R)-2-hydroxy-6,10,14-trimethylpentadecan-2-yl)-4,6,7-trimethyl-2,3-
dihydrobenzofuran-5-ol (150) 
 
To a solution of 35 mg 
epoxide 149 (46 μmol, 1.0 
eq.) in 1 mL THF was added 
at r.t. 100 μL of TBAF (1 M 
in THF) (100 μmol, 2.2 eq.). The reaction mixture was stirred for 1 h at r.t. The 
reaction was then quenched with saturated NaHCO3 and the mixture was extracted 
with ether. The combined organic phases were dried over Na2SO4. Chromatography 
(SiO2, hexane/EtOAc = 4:1) afforded 18 mg (40 μmol, 87%) of a colourless oil. 
 
TLC (SiO2, hexane/EtOAc = 4:1): Rf = 0.22. 
1H-NMR (500 MHz, CDCl3): 0.83-0.88 (m, 12H, C13/17/21-CH3), 1.00-1.58 (m, 21H, 
H10/11/12/13/14/15/16/17/18/19/20/21), 1.32 (s, 3H, C9-CH3), 1.79 (s, 1H, OH) 2.12 (s, 3H, C2/3/6-
CH3), 2.13 (s, 6H, C2/3/6-CH3), 2.99 (dd, J = 9.2, 15.4 Hz, 1H, H7), 3.12 (dd, J = 9.2, 
15.4 Hz, 1H, H7), 4.15 (s, 1H, OH), 4.55 (t, J = 9.2 Hz, 1H, H8). 
13C-NMR (125 MHz, CDCl3): 12.1, 12.3, 13.0, 19.8, 19.9, 20.9, 22.8, 22.9, 23.5, 24.6, 
25.0, 28.1, 30.3, 33.0, 37.4, 37.51, 37.58, 37.61, 37.9, 39.5, 73.7, 88.2, 115.7, 117.3, 
121.4, 123.4, 145.8, 151.5. 
HPLC (Chiralcel OD-H, heptane/isopropanol = 90:10, 0.5 mL/min, 220 nm): t = 
11.3 min (51%), t = 12.1 min (49%). 
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5.2.6 Synthesis of α-Tocopherol (1) via Epoxide 148 
 
(3R,7R,11R)-1-(2-(tert-butyldiphenylsilyloxy)-5-methoxy-3,4,6-trimethylphenyl)-
3,7,11,15-tetramethylhexadecan-3-ol 
 
To 172 mg of epoxide 
148 (247 μmol, 1.0 eq.) 
were added 7.4 mL of 
Super-Hydride®-
Solution (1.0 M in THF, 7.4 mmol, 30 eq.). The mixture was heated at reflux for 4 h. 
The solution was cooled to 0 °C and 70 mL wet DCM was carefully added followed 
by 70 mL of H2O. Two spatulas of solid NH4Cl were added so that both phases 
became clear. The phases were separated and the aqueous phase was further 
extracted with DCM. The combined organic phases were dried over Na2SO4. 
Chromatography (SiO2, hexane/EtOAc = 10:1) afforded 85 mg (121 μmol, 49%) of a 
colourless oil. 
 
TLC (SiO2, hexane/EtOAc = 20:3): Rf = 0.28. 
1H-NMR (500 MHz, CDCl3): 0.65 (s, 1H, OH), 0.86-0.93 (m, 12H, C13/17/21-CH3), 0.95 
(s, 3H, C9-CH3), 1.05-1.45 (m, 20H, H10/11/12/13/14/15/16/17/18/19/20), 1.41-1.44 (m, 2H, H8), 
1.52 (sept, 1H, J=6.6 Hz, H21), 1.89 (s, 3H, C3-CH3), 2.06 (s, 3H, C2-CH3), 2.15 (s, 
3H, C6-CH3), 2.49-2.52 (m, 2H, H7), 3.62 (s, 3H, CH3O), 7.31-7.35 (m, 4H, Hm DPS-), 
7.38-7.43 (m, 2H, Hp DPS-), 7.70 (t, 4H, J=6.6 Hz, Ho DPS-) ;  
13C-NMR (125 MHz, CDCl3): 12.4 (C6-CH3), 13.1 (C2-CH3), 15.9 (C3-CH3), 19.86, 
19.90, 20.47, 21.48, 22.77, 22.87, 22.91, 24.66, 24.94, 25.74, 27.15, 28.12, 32.96, 
37.43, 37.59, 37.77, 39.51, 41.63, 41.66, 43.06, 60.35 (CH3O), 72.72 (C9),  125.32 
(C3), 126.99 (C6), 127.68 (Cm, DPS-), 127.75 (C2),  127.96 (C5), 129.75 (Cp, DPS-), 
134.45 and 134.59 (CSi,diastereotopic, DPS-), 135.38 (Co, DPS), 148.31 (C4), 151.59 (C1);  
MS (EI): m/z (%) = 700.5 ([M+], 16), 377.2 (100), 359.2 (85), 299.1 (76). 
EA: calculated for C46H72O3Si: C 78.80, H 10.35; found: C 78.49, H 10.22. 
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2-((3R,7R,11R)-3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-
trimethylcyclohexa-2,5-diene-1,4-dione (159) 
 
79 mg of protected 
hydroquinone 158 (113 
μmol, 1.0 eq.) was 
dissolved in 5 ml MeCN. A 
solution of 139 mg of CAN (252 μmol, 2.2 eq.) in 520 μLH2O was added dropwise at 
r.t. The mixture was stirred for 1h at r.t. DCM and H2O were added and the phases 
were separated. The aqueous phase was further extracted with DCM. The combined 
organic phases were dried over Na2SO4. Chromatography (SiO2, hexane/EtOAc = 
4:1) afforded 42 mg (94 μmol, 83%) of a yellow oil. 
TLC (SiO2, hexane/EtOAc = 4:1): Rf = 0.28. 
1H-NMR (500 MHz, CDCl3): 0.82-0.88 (m, 12H, C13/17/21-CH3), 1.0-1.55 (m, 24H, 
H8/10/11/12/13/14/15/16/17/18/19/20/21/OH), 1.23 (s, 3H, C9-CH3), 2.01 (s, 6H, C3/2-CH3), 2.03 (s, 
3H, C6-CH3), 2.50-2.58 (m, 2H, H7).  
 
(2R,4’R,8’R)-α-Tocopherol (1) 
 
A mixture of 42 mg of quinone 
159 (94 μmol, 1.0 eq.), 8 mg 
Pd/C (10%) and 7 ml MeOH 
were stirred at r.t. under an 
atmosphere of hydrogen for 12 h. The catalyst was filtered, and the filtrate was 
concentrated in vacuo. Because of the tendency to air oxidise, the hydroquinone so 
obtained was immediately dissolved in 4.2 mL benzene and 4.1 mg pTsOH·H2O (22 
μmol, 0.23 eq.) were added. The solution was heated to 80°C for 1.25 h. The mixture 
was cooled down to r.t. and treated with saturated NaHCO3. The mixture was 
extracted with ether (3x) and the combined organic phases were dried over Na2SO4. 
Chromatography (SiO2, hexane/EtOAc = 10 : 1) afforded 37 mg (86 μmol, 92%) of a 
colourless oil. 
 
TLC (SiO2, hexane/EtOAc = 20:3): Rf = 0.40. 
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HPLC (Chiralcel OD-H, 0.5% EtOH in hexane, 1.0 mL/min, 220 nm): t(2R) = 7.6 min 
(96.5%); t(2S) = 8.8 min (3.5%). 
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6 Appendix 
 
6.1 List of Abbreviations 
 
μL microliters 
μmol micromole 
AcOH  acetic acid 
aq.  aqueous 
atm   atmosphere 
calc.  calculated  
CAN   ceric ammonium nitrate 
CTG  cyclodextrin glucosyl transferase 
CD  cyclodextrin 
d   doublet  
DCM   dichloromethane 
de   diastereomeric excess 
DME  dimethoxyethane 
DMF  N,N'-dimethylformamide  
DMP    2,2-dimethoxypropane  
DMSO  dimethylsulfoxide 
DPS   tert-butyldiphenylsilyl 
EA  elemental analysis  
EDTA   ethylenediaminetetraacetic acid 
ee   enantiomeric excess 
EI-MS  electron impact mass spectra  
Ent  enantiomer 
EP  Enzyme Product 
ESI-MS Electron Spray Ionization Mass Spectra  
Et2O   diethyl ether 
EtOAc  ethyl acetate 
EtOH   ethanol 
eq.  equivalents 
ES   Enzyme Substrate  
FTIR  Fourier Transform Infrared Spectroscopy  
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GC   Gas Chromatography 
h hours 
HPLC  High Performance Liquid Chromatography 
IR  infrared spectrum 
J  coupling constant in Hertz. 
m  multiplet 
mCPBA meta-chloroperoxybenzoic acid 
MDT   Marine Derived Tocopherol  
Me  methyl 
MeCN  acetonitrile 
MeOH  methanol  
min   minutes  
mL  milliliters 
mmol   millimole 
M  molar  
MOM  methoxymethyl 
mp   melting point  
m/z  mass/charge 
Ms  methanesulfonoyl 
MS  mass spectroscopy 
NMO  N-methylmorpholine-N-oxide   
NMR   Nuclear Magnetic Resonance 
ox.  oxidation  
p  para 
PCC  Pyridinium Chlorochromate 
ppm  parts per million  
PPNO  4-phenylpyridine N-oxide 
PDC   pyridinium dichromate 
q   quartet 
r.t.  room temperature 
rac  racemic 
red.  reduction 
Rf  Retention Factor (chromatography) 
s   singlet 
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SiO2  silica gel 
SN2  bimolecular nucleophilic substitution 
SOMO  single-occupied molecular orbital 
t   triplet 
TBAF  tetra-N-butylammonium fluoride 
TBHP  tert-butyl hydroperoxide 
TBME  tert-butyl-methyl ether 
TBS   tert-butyldimethylsilyl 
tBu  tert-butyl 
TFA   trifluoroacetic acid 
THF   tetrahydrofuran 
TIPSCl  triisopropylsilylchloride 
TLC  analytical thin layer chromatography  
TMC  transition Metal catalysis 
TMEDA  tetramethylethylenediamine 
TMS   tetramethylsilane 
TPA   tris(2-pyridylmethylamine) 
Ts  tosyl/p-toluenesulfonyl  
α-TTP  α-Tocopherol Transfer Protein  
UV  Ultra-Violet 
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